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Platelets are the smallest, yet arguably the most pivotal blood constituent in the context of 
haemostasis and wound healing. However, vascular perturbations that result in ischaemic tissue 
injury has implicated platelets as a major player in the disease progression caused by arterial 
thrombosis. Platelets responses are influenced by the auto- and paracrine release of prothrombotic 
ligands acting upon platelet-expressed G-protein coupled receptors (GPCRs). These receptors initiate 
distinct intracellular signal pathways responsible for the interrelated processes of platelet adhesion, 
activation, secretion and aggregation. Of the many platelet expressed GPCRs, the activation of the 
P2Y12 receptor (P2Y12R) is well known to be responsible for sustained aggregation and thus thrombus 
formation. Consequently, the P2Y12R is an attractive and efficacious target for drug development, 
birthing the modern standard of care of dual antiplatelet therapy (DAPT) in patients with acute 
coronary syndromes (ACS). Of the currently available antiplatelet agents, ticagrelor has been shown 
to be superior both in clinical trials and laboratory studies. However, much debate exists around the 
pharmacodynamics attributed to ticagrelor and how this may influence its perceived clinical 
superiority. Additionally, amid concerns of the increased bleeding risk associated with ticagrelor as 
with all antiplatelet agents, recent international expert consensus guidelines have emerged to 
provide clarity on how and when to switch pharmacotherapies. Therefore, the aim of this thesis was 
to further define the pharmacodynamics of ticagrelor antiplatelet therapy, characterising the drugs 
mode of action, onset and reversibility. Assessment of the inhibitory effect of ticagrelor on P2Y12R 
activation was facilitated by bioluminescence resonance energy transfer (BRET2) technology in 
P2Y12R-transfected cells and complemented by observations seen with light transmission 
aggregometry in isolated human platelets. Our results demonstrate that ticagrelor acts as an inverse 
agonist in a concentration-dependent manner. Further, the proposed reversibility of this drug is 
questioned with data suggesting that versus ADP, this drug acts in an irreversible manner. This may 
impact upon clinical practice regarding antiplatelet therapy administration, especially in 
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Chapter 1: Introduction 
1.1. Acute coronary syndromes  
Cardiovascular disease (CVD) is an umbrella term used to describe a group of disorders related to the 
heart and blood vessels. Encompassed within this anatomical classification are the following: 
coronary heart disease (CHD), coronary artery disease (CAD) and acute coronary syndromes (ACS). 
Coronary heart disease results from the pathogenesis of coronary artery disease, characterised by 
the accumulation of unstable atherosclerotic plaque (atheroma) within the vasculature (Sanchis-
Gomar, Perez-Quilis et al. 2016). 
The development of an atheroma within the coronary vasculature may be asymptotic, and therefore 
CAD may be unrecognised until a time at which symptoms arise. At advanced stages in the disease 
progression, whereby the accumulated atheroma is liable to rupture, the plaque and constituents 
may travel antegrade to occlude narrowing coronary vessels. The clinical manifestations attributed 
to this occlusion of coronary vessels include angina, shortness of breath, nausea and sweating (Lippi, 
Sanchis-Gomar et al. 2016). At this time, a patient presenting with these symptoms is likely to be 
suffering from an acute coronary syndrome (ACS) (Lippi and Cervellin 2016).  
ACS is further sub-categorised into unstable angina (UA) or myocardial infarction (MI). The former 
refers to a partial occlusion that may dissolve to re-occlude the vessel further antegrade, 
nevertheless producing discomfort and perceived chest pain. MI refers to the total occlusion of a 
coronary vessel, whereby the heart tissue that is being served by the occluded vessel begins to die, 
a cellular process of necrosis resulting from ischaemic hypoxia (Konstantinidis, Whelan et al. 2012).  
Regardless of the relative severity of each acute coronary syndrome, these advanced stages of CVD 
progression are well known as the major player in the alarmingly high mortality rate attributable to 
these group of disorders.  
 
1.2. Prevalence/incidence/mortality rates:  A global perspective 
Recent breakthroughs in medical technology have enabled clinicians to utilise novel, highly sensitive 
cardiac troponin immunoassays to more successfully and accurately diagnose MI (Carlsson, 
Bandstein et al. 2017). Consequently, the treatment and therapy of patients presenting with acute 
coronary syndromes in the developed world has improved drastically, and is reflected by the 





Quilis et al. 2016). However, CVD still remains the number one cause of death globally (World Health 
Organisation 2017) (Figure 1.1.). 
In a 2019 update of heart disease and stroke statistics, the American Heart Association (AHA) 
reported that 18.2 million people residing in the United States over 20 years of age had CHD. 
Moreover, estimating that every 40 seconds an American will suffer an MI (Benjamin, Muntner et al. 
2019). Similarly harrowing reports have existed for over a decade, long attributing CHD as a major 
cause of premature death and disability (Roger 2007). In addition, CHD is responsible for a third of 
all deaths in people older than 35 years of age (Nichols, Townsend et al. 2014). This prevalence and 
trend in mortality has long been reflected among similarly developed countries around the world 
(Levi, Lucchini et al. 2002).  
Figure 1.1. Top 10 global causes of death, 2016. Ischaemic heart disease and stroke are the top 2 
causes of death, respectively (World Health Organisation 2017). 
It is estimated that each year, 3.9 million Europeans are killed by CVD, accounting for 45% of the total 
mortality rate within the continent (Wilkins, Wilson et al. 2017). Further, the European Heart 
Network (EHN) estimates that more than 85 million Europeans were living with CVD in 2015.  





leading causes of death in the United Kingdom, aligning with similar trends in mortality rates within 
the developing world (Timmis 2015).   
CVD is largely well-known as a preventable, non-communicable disease. Exposure to various risk 
factors that influence the progression of CAD; bad nutrition practices, physical inactivity and smoking 
are highly attributed to the development and progression of the disease (Danaei, Ding et al. 2009) 
(Figure 1.2.). Aligning with this, the EHN attribute dietary factors to provide the largest contribution 
to the risk of CVD mortality above all other behavioural factors (Wilkins, Wilson et al. 2017). Raised 
systolic blood pressure is one of the largest contributors in respect to risk of CVD and CHD (Yano, 
Stamler et al. 2015). As such, increased sedentary and obesogenic lifestyles within developed 
western countries may provide at least a partial explanation to the problem.  
For example, the global fast-food industry has been projected to be valued at a staggering USD $843.4 
billion by 2026 (ResearchStraits. 2019). Thus, highlighting the extent of the demand and abundance 
of relatively cheap, easily accessible, and unhealthy nutrition alternatives in an ever-expanding 
market of consumers. This draws insight into the correlation between comorbidities associated with 
obesity and resulting CVD (see Fig 1.2). 
Figure 1.2. Pathogenesis of CVD and ACS. Healthy coronary vessels become occluded with the 
accumulation of atherosclerotic plaque, influenced by the contribution of various risk factors of CAD, 





As developing countries begin to emerge on the world stage, and their growing populations become 
subject to increased post-modern industrialisation, it has been projected that CHD mortality will 
double from 1990 to 2020 (Okrainec, Banerjee et al. 2004). Okrainec and colleagues further suggest 
that rapid socioeconomic growth coupled with greater exposure to the risk factors for CAD, will 
compound with the relative lack of preventative measures available, to demonstrate similar trends 
in mortality and economic burden that exists within developed, western countries.  
 
1.3. Economic implications  
It is estimated that CVD generates a loss of €210 billion to the EU economy every year. Of that total 
loss; ~53% due to health care costs, ~26% to productivity losses and ~21% to the informal care of 
CVD patients (Wilkins, Wilson et al. 2017). Similar reports exist in respect to the cost of CVD to the 
economy of the U.S., a figure estimated to be approximately USD $213 billion (DeVol, Bedroussian et 
al. 2007). Collectively, these estimations reveal the gravity of the socioeconomic burden of CVD and 
consequently highlights the importance of mitigating the prevalence of the disease, additionally in 
the context of healthcare resource conservation.  
Knowledge of the contributing behavioural and dietary factors implicated in the disease progression 
is understood by the general public with government-led public health intervention strategies to 
mitigate the rise of obesity-related CVD (Pell, Penney et al. 2019). For example, the introduction in 
the UK of the soft drinks industry levy (SDIL) in April 2018. The British government introduced 
additional taxation on high sugar-containing drinks to provide a tangible and concerted deterrence 
to the projected increased prevalence of obesity, targeting the beverage industry in the United 
Kingdom (Lifestyles Team 2019). Consequently, industry was incentivised to reformulate their 
respective beverages to align with government policy, where the increased revenue generated would 
be used as public health investiture for preventative initiatives and education regarding childhood 
obesity. The public health initiative sought to change individuals’ unhealthy behaviour with the aims 
of improving their health and to conserve healthcare resources (Veliz, Maslen et al. 2019). Ultimately, 
the SDIL incentivises consumers to purchase less of the beverage whilst simultaneously igniting 
industry-wide reformulation, reducing sugar content. Proving to be a powerful and successful 





2018, sugar content within drinks subjected to the SDIL decreased by 28.8% (Niblett, Coyle et al. 
2019).   
Public health initiatives in the form of taxation have long existed, similarly showing efficacy in 
decreasing consumption with regards to tobacco (Chaloupka FJ, Yurekli A et al. 2012) and alcohol 
(Elder, Lawrence et al. 2010). Although showing promise in the deterrence of the development of 
obesity with the example of the SDIL, it constitutes a relatively small concession in the array of 
contributing factors of CVD. Further, the beverage industry is merely a constituent of the problem 
where arguably, the fast food industry precedes (Bahadoran, Mirmiran et al. 2015). Thus, albeit a 
step in the right direction, the ability to tangibly decrease CVD prevalence rests with the consumer. 
As developing countries emerge on the world stage, rapid socioeconomic growth and cultural shifts 
predicated towards more sedentary lifestyles, coupled with the projected growth of the global fast-
food industry, the overall global prevalence of CVD and ACS appears unlikely to decrease with respect 
to time. Thus, the consideration that the disease is mutually exclusive to industrialised countries 
appears short-sighted. Therefore, the focus shifts towards the improvement of current interventional 
therapies available to patients that develop ACS, and by enhancing the collective understanding of 
the available pharmacotherapies to optimise their use within clinical practice, thus generating more 
positive patient outcomes that can be reflected globally. 
Coronary vessel occlusion, underpinning the clinical manifestations of ACS, begins with the 
generation and propagation of an atheroma at the luminal wall of a coronary artery. The atheroma 
is comprised of accumulated fatty deposits and scar tissue that eventually grows large enough to 
either occlude the vessel itself, or rupture to occlude narrowing vessels further antegrade (Figure 
1.2.). With the rupture of an atheroma, the extracellular matrix (ECM) of the vessel is exposed to 
circulating quiescent platelets within the blood. This leaves platelets liable to adhere to these 
thrombogenic extravascular sites, ultimately propagating the generation of arterial thrombosis 
(Jackson 2011).  
Through a complex interplay of tightly regulated intracellular signalling pathways, mediated by 
several surface-expressed proteins and their respective ligands, the pathophysiology of platelet 
responses has been well-studied in the context of wound healing and primary homeostasis 
(Golebiewska and Poole 2015). However, due to the role platelets play in the context of vascular 





1.4. Platelets and Megakaryocytes  
Platelets (thrombocytes) are bioactive cellular fragments that enter the circulatory system after 
maturation steps of their progenitor, the megakaryocyte (MK). MKs are located within the bone 
marrow. The generation of MKs begins with a series of mechanistic steps of differentiation in 
haematopoietic stem cells (HSC). Consequently, the ability of HSC to commit their lineage to the 
maturation, and production of megakaryocytes relies on the presence of chemokines and other 
factors within their microenvironment.  A process largely well known as megakaryopoiesis.  
Figure 1.3. Megakaryocyte morphology. Confocal image of bone marrow sample. Megakaryocytes are 
indicated by the white arrows. Scale bar = 30µm. Authors grant permission for the re-use of this 
image in this thesis (Eckly, Strassel et al. 2009).  
As a result of this tightly regulated differentiation, megakaryocytes perform their unique cellular 
process of maturation, endomitosis. A process extensively studied; the mechanism elucidated as an 
abortion of mitosis in late anaphase of the cell cycle, driven by thrombopoietin (TPO) ligand binding 
at MK-specific receptor, c-Mpl (Machlus, Thon et al. 2014) (Patel, Hartwig et al. 2005). The 
endomitotic nature of the MK cell cycle enables MKs to generate progressive polyploidy, 
accumulating large nuclear mass and additionally increasing cytoplasmic volume, without division 
(Geddis and Kaushansky 2006). Thus, mature MKs appear large morphologically at 30-100um in 
diameter, and can be characterised by their unique polylobate nucleus (Figure 1.3.), in addition to 
their invaginated membrane system (IMS) (Thon and Italiano 2012). 
Derived from the plasma membrane, the IMS functions primarily as a membrane reservoir for the 
MK, permeating the cytoplasm and facilitating subsequent proplatelet evagination events. It is only 





bone marrow, to subendothelial regions near venous sinusoids (Guo, Wang et al. 2015). Here, the 
MK elongates its proplatelet pseudopodia via the polymerisation of the microtubule cytoskeleton, 
initiated within the cell body, towards the periphery (Machlus, Thon et al. 2014). Consequently, the 
elongation of these cytoplasmic extensions penetrates the luminal wall of the endothelium, whereby 
the proplatelet extensions fragment, releasing thousands of nascent platelets into the bloodstream 
(Patel, Hartwig et al. 2005). This process continues with the successive budding of the MK cytoplasm, 
until eventually depleted and the entirety of the remaining cell body is transformed into proplatelets. 
Subsequently shed as platelets into the circulation, facilitated by shear from the luminal flow of blood 
(Guo, Wang et al. 2015). Thus, platelets can be thought of as fragmented, bioactive blood 
constituents of their precursor MK. 
 
1.5. Platelet structure/ultrastructure  
Platelet structure has been studied extensively, and is widely accepted as having a biconvex, discoid 
shape when quiescent. Typically measuring 2-3um in diameter, they are widely known to be the 
smallest constituent of whole blood and interestingly, one of the most numerous; 150,00-
400,000/uL. 
Although described as bioactive cytoplasmic fractions of the MK, they inherit organelles and 
specialised structures of traditionally described cells. Platelets have extensive plasma membrane 
expression of glycoproteins and contain inherited cytoplasmic structures from the MK; dense 
granules, alpha granules and lysosomes (Figure 1.4.). However, unlike traditionally characterised 
cells, platelets lack a nucleus. Additionally, they possess two distinct internal membrane systems. The 
dense tubular system (DTS) and the open canalicular system (OCS) (Rumbaut and Thiagarajan 2010).  
The absence of a nucleus underscores the relatively expendable nature of platelets, unneeded after 
performing their functional responses in the context of vascular homeostasis.  As such, the lifespan 
of the platelet is relatively short at just 10 days. Thus, the TPO-mediated proliferation and maturation 
of the MK is paramount in the biogenesis of new platelets. 
The DTS exists as an internal membrane system for the platelet and is thought to be derived from 
the MK endoplasmic reticulum (Gerrard, White et al. 1978). Structurally, it can be thought of as thin 
and elongated membrane extensions within the platelet. It functions primarily as an intracellular sink 





Tewfik and Flaumenhaft 2013). Membrane-expressed calcium channels mediate ionic flux from the 
DTS. Analogous to the ion channels in the sarcoplasmic reticulum of skeletal muscle cells. 
Importantly, the DTS lacks continuity with the outer surface of the plasma membrane and is only 
interconnected with the OCS at one or two sites, forming uncommon membrane complexes.  
The OCS of the platelet is an additional internal membrane system, playing a critical role in the 
facilitation of various functional responses upon platelet activation. Continuous with the plasma 
membrane surface, the OCS permeates the cytoplasm of the platelet in the form of a network of 
interconnected tubular canaliculi (White and Clawson 1980).  
Figure 1.4. Platelet ultrastructure. TEM image of a human platelet, highlighting their unique 
intracellular features. Scale bar = 0.5um. Authors grant permission for the re-use of this image in this 
thesis (Selvadurai and Hamilton 2018). 
The OCS lipid composition is identical to that of the plasma membrane of the platelet, invaginating 
to provide a source of membrane reserve. Additionally it contains numerous surface expressed 
glycoproteins (Selvadurai and Hamilton 2018). Further, the ability of the platelet to become activated 
and subsequently perform its functional responses relies heavily on the interactions of these 
glycoproteins with a wide range of substrates within their vascular niche.  
Once released into the bloodstream, nascent platelets are inhibited from activation with the release 
of soluble nitric oxide (NO) and prostaglandin I2 (PGI2) from healthy endothelial cells (Jurk and Kehrel 





becomes compromised, facilitating initial adhesion events via one of their many types of surface 
expressed glycoproteins (GP), termed integrins. 
Ultimately, the platelets’ role as orchestrators of primary homeostasis pivots on the ability of the 
platelet to sense vascular damage within the microenvironment and to respond accordingly with the 
transduction of complex intracellular signalling cascades. Platelets initiate and propagating a series 
of functional responses: adhesion, activation, granule secretion and finally, aggregation. 
 
1.6. Adhesion 
Integrins constitute a superfamily of cell-surface GP receptors that are widely expressed in 
mammalian tissues. They exist as heterodimeric transmembrane GP complexes, consisting of 2 non-
covalently bound alpha and beta subunits. Each respective subunit has a large N-terminal 
extracellular ectodomain and additionally contains a relatively short (20-60 amino acids) intracellular 
C-terminal tail that provides a docking site for various cytoplasmic proteins.  Integrins allow platelets 
to initiate signalling cascades in response to the ligand in a bidirectional manner. Bidirectional 
transfer of information across the plasma membrane that facilitates inside-out and downstream 
outside-in signalling events, ultimately propagating platelet activation. Thus, although previously 
simply thought of as adhesion proteins, integrins serve as highly dynamic regulators of platelet cell 
function (Durrant, van den Bosch et al. 2017). 
At the site of injury within the luminal wall of the vasculature, the ECM of the underlying sub-
endothelium becomes exposed to the circulating constituents of the blood. Freely circulating von 
Willebrand factor (VWF) binds to the exposed collagen, effectively immobilising the soluble protein 
(Reininger, Heijnen et al. 2006). Consequently, platelets initially adhere to these thrombogenic pro-
inflammatory sites, which serve as ECM ligands with affinity for the platelet-expressed GPIb-IX-V 
complex and GPVI. The (GP) Ib-IX-V exists as four subunits with the interaction of this complex with 
immobilised VWF facilitating the slowing of the platelets to the site of vessel injury (Li and Emsley 
2013). Additionally, the interaction of GPVI and collagen initiates clustering of the integrins whilst 
concurrently increasing the affinity of integrins; α2β1 and αIIbβ3 (Nieswandt, Pleines et al. 2011). 








During activation, the platelet undergoes drastic morphological changes resulting in the 
manipulation of its OCS. The invaginating membrane system functions as a reservoir for the platelet, 
facilitating a store of membrane that can be rapidly mobilised, crucial in the context of shape change. 
Thus, upon activation, the platelet rapidly undergoes cytoskeletal polymerisation events resulting in 
a change of shape from discoid to spherical, beginning with the disassembly of the circumferential 
microtubule ring, eventually generating outward projections of filopodia and lamellipodia (Paul, 
Daniel et al. 1999). 
An additional consequence of platelet activation results in the priming of GP IIb/IIIa. The integrin 
exists as a heterodimer, consisting of an alpha (αIIb) and beta (β3) subunit (Rumbaut and Thiagarajan 
2010). When resting, platelets express around 80,000 copies of the integrin on their surface, in an 
inactive ‘closed’ conformation. The integrins’ nodular head of the ectodomain is kept in a bent over, 
‘V’ shape, whereby the ligand binding site is inaccessible and kept in a low-affinity state (Durrant, van 
den Bosch et al. 2017). Once the platelet becomes activated, the integrin undergoes a conformational 
change in the headpiece whereby each subunit separates, exposing the ligand binding site and thus 
increasing affinity. Consequently, the integrin is liable to bind to a range of ligands such as vitronectin, 
fibronectin, VWF and notably fibrinogen. 
These morphological changes of the OCS, in addition to the dynamic regulation of surface expressed 
integrins, enables the platelet to spread at the site of the injured vessel to increase its respective 
surface area, whilst generating an adhesive monolayer for the recruitment of additional platelets. 
Shape change is known to be reliant on the ability of the DTS to flux calcium, acting as an important 
substrate for the cytoskeletal and contractile machinery within the cytosol. Further calcium flux is 
implicated as a modulator of prostaglandin synthesis (Gerrard, White et al. 1978) and further 
facilitates the translocation of cytoplasmic alpha and dense granules and lysosomes to fuse with the 
plasma membrane, resulting in platelet secretion. 
 
1.8. Secretion 
The secretion of the cytoplasmic contents of the platelet is facilitated via a mechanism termed 
exocytosis. Upon platelet activation, granules become localised centrally whereby they may fuse with 





Rapid cytoskeletal polymerisation of F-actin facilitates transport of the granules to the periphery of 
the platelet, interacting directly with soluble NEM-sensitive attachment protein receptors (SNAREs) 
(Woronowicz, Dilks et al. 2010).  SNAREs are a significant element of the secretory machinery at the 
OCS/plasma membrane. However, not all SNAREs are the same. Classified according to their 
respective localisation to the outer membrane of vesicles (vSNAREs) or the cytosolic face of the target 
membrane (tSNAREs). Vesicle-associated membrane protein 8 (VAMP8) is known to be the most 
dominant in platelets. Platelet tSNAREs; SNAP-23, syntaxin 2 and syntaxin 4 regulating platelet 
granule secretion. Additionally, the involvement of SNARE-associated protein, Munc18 and the 
GTPase, RAB27b are implicated (Golebiewska and Poole 2015).  
Alpha granules are the largest and most prevalent granules. Alpha granules primarily contain; larger 
polypeptides including chemokines, growth factors, adhesion molecules as well as factors involved 
in coagulation and aggregation (vWF and fibrinogen) (Rumbaut and Thiagarajan 2010). The smallest 
granules, termed dense granules, contain small molecules; serotonin (5HTP), calcium (Ca2+) and 
additionally nucleotides; adenosine diphosphate (Figure 1.11.)(ADP) and adenosine triphosphate 
(ATP) (Rendu and Brohard-Bohn 2001). Once translocated to the plasma membrane, the contents 
are released into the OCS, eventually diffusing into the extracellular space. 
Irrespective of the type of granule secreted, the purpose of their release is to ultimately enable the 
recruitment (chemotaxis) and further activation (amplification) of platelet responses. This is 
mediated by subsequent outside-in signalling via surface expressed G-protein coupled receptors 
(GPCRs). This, a well-described mechanism of positive feedback is a fundamental contributor to the 
platelets’ final functional response after activation, aggregation.  
 
1.9. Aggregation 
Aggregation refers to the physical interaction between adjacent activated platelets via the molecular 
cross-linking of their respective ‘primed’ GP IIb/IIIa, bound by extracellular fibrinogen, forming a 
bivalent bridge (Figure 1.6). The released constituents of granule secretion act as endogenous ligands 
at a wide range of surface expressed GPCRs, with receptor activation initiating distinct intracellular 
signalling events that essentially converge, increasing the robustness of platelet responses. The 





signalling; ultimately resulting in dynamic changes within the platelet, bolstering their physiologically 
indicated effectiveness.  
In the context of wound healing and primary haemostasis, this final functional response of 
aggregation is widely beneficial, resulting in the consolidation of the platelet plug, attenuating blood 
loss. However, in the context of metabolic disease that results in the generation of an atherosclerotic 
plaque liable to rupture (CAD), the platelet’s aggregatory response directly implicates them as 
significant players in arterial thrombosis (Jackson 2011), which underpin the platelet contribution to 
the pathogenesis and clinical manifestations attributed to ACS. The complexity of the mechanisms 
underlying their functional responses is bolstered by the remarkable variety of membrane bound 
GPCRs, and their distinct signal transduction pathways.  
 
1.10. The GPCR-G-protein complex 
GPCRs constitute the largest class of membrane proteins existing in the human genome (Alexander, 
Christopoulos et al. 2019). They share a similar structure across all receptor types, consisting of a 
single polypeptide with an extracellular N-terminus, 7 membrane spanning hydrophobic helices and 
an intracellular C-terminus. Additionally, as alluded to within the name, these receptors signal 
through preferential coupling to distinct intracellular heterotrimeric G-proteins (Purves, Augustine 
et al. 2001). 
G-proteins are heterotrimers, comprised of 3 subunits: alpha (α), beta (β) and gamma (γ). The α 
subunit containing a nucleotide binding pocket with GTPase activity. Whilst the β and γ subunits exist 
as a heterodimer (Gβγ). In unstimulated receptors, GDP is bound within the α subunit with Gβγ-
association inhibiting GDPs release. This stabilises the heterotrimeric protein in an inactive 
conformation. Following GPCR activation, the G-protein complex binds to the stimulated GPCR; 
rapidly exchanging GDP for GTP. This results in the dissociation of the respective α and βγ subunits. 
Thus, the GPCR-G-protein complex becomes disassembled, and each subunit is free to activate 
various downstream effectors (Jastrzebska 2013). 
G-proteins are classified into four subfamilies according to the structural similarity of their alpha 
subunits and the type of modulatory response that they are responsible for. The subfamilies are 
classified as the following: Gαs, Gαi/o, Gαq/11 and Gα12/13 (Jastrzebska 2013). Platelet receptor 





Hence, allowing tightly controlled modulation of various cytosolic target proteins. The differential 
coupling of the monomeric G-protein alpha subunits to the various receptor subtypes of; protease-
activated receptors (PAR), Thromboxane receptors (TP), prostanoid receptors (IP) and crucially the 
purinergic receptors (P2Y1 & P2Y12) of platelets drives distinct intracellular signal transduction 
pathways stimulating platelet activation.   
 
1.11. Endogenous inhibitory signalling  
In an unperturbed vascular environment, endothelial cells (ECs) synthesise and constitutively release 
the endogenous prostaglandin, prostacyclin (PGI2) as well as nitric oxide (NO) and other anti-
inflammatory mediators (Kanthi, Sutton et al. 2014). The platelet utilises the former, an eicosanoid, 
as an agonist at the prostacyclin receptor (IP), resulting in Gαs-mediated signal transduction 
(Alexander, Christopoulos et al. 2019). Dissociation of Gαs directly stimulates the activation of 
adenylate cyclase (AC); a membrane bound enzyme responsible for the catalysis of ATP to cyclic 
adenosine monophosphate (cAMP). Receptor activation leads to an approximate 10-fold increase in 
cytosolic [cAMP]. This cAMP in turn robustly dampens pro-thrombotic signal transduction (Midgett, 
Stitham et al. 2011). This is further evidenced by studies demonstrating the powerful ability of 
prostacyclin to rapidly reverse platelet aggregation (Best, Martin et al. 1977).  
Additionally, ECs generate and secrete NO facilitating vasodilation and additionally inhibiting the 
breakdown of cAMP via the inhibition of phosphodiesterases (PDEs) (Stalker, Newman et al. 2012). 
Moreover, EC’s express an additional membrane protein responsible for modulating platelet 
responsiveness, CD39. This evolutionarily conserved ectonucleotidase catalyses extracellular ATP 
and ADP into AMP; concurrently degrading the pro-thrombotic ligand for the purinergic platelet 
receptors (ATP/ADP) whilst providing the cell an excess of substrate for inhibitory signal transduction 
(cAMP) (Kanthi, Sutton et al. 2014). Further, the generated adenosine resulting from nucleotide 
degradation; via CD39, acts as endogenous ligands for the Gαs-coupled adenosine receptor (A2A). 
Activation of this receptor whereby activation similarly enhances generation of cAMP (Fuentes, 
Fuentes et al. 2018).    
Ultimately, the ability of ECs to constitutively release endogenous ligands serves as a brake to the 
positive feedback signal amplification that results from the auto- and paracrine secretion of platelet 





1.12. Stimulatory platelet receptors 
 
1.12.1. Protease activated receptors (PARs) 
Protease-activated receptors (PARs) are unique GPCRs. They are activated following a proteolytic 
cleavage within their first extracellular loop, generating a new N-terminus that functions as a 
tethered ligand (Rivera, Lozano et al. 2009). The receptor relies on proteolytic cleavage to become 
activated. Endogenous serine proteases localised at sites of vessel injury, including thrombin, are 
responsible. In human platelets, stimulating PAR-1 and PAR-4 via thrombin generates a 
comprehensive range of responses that directly trigger platelet activation and subsequent 
aggregation. PAR-1 and PAR-4 are known to couple to both Gαq and Gα12/13 (Rumbaut and 
Thiagarajan 2010). Thus, stimulating these receptors with the agonist thrombin, initiates 2 distinct 
signalling pathways attributed to each Gα subunit.  
Gαq stimulates phospholipase C (PLC), catalysing the liberation of diacyl glycerol (DAG) and inositol 
triphosphate (IP3) from membrane-bound phosphatidylinositol-(4,5)-bisphosphate (PIP2). The 
products; DAG and IP3, are second messengers, facilitating the downstream activation of protein 
kinase C (PKC) which in turn stimulates the release of Ca2+ from the DTS (Woulfe 2005). Conversely, 
Gα12/13 dissociation results in the activation of the small GTPase, RhoA and Rho kinase (RhoK). Both 
are implicated in the phosphorylation of myosin light chain kinase (MLCK); crucial in the modulation 
and reorganisation of the actin cytoskeleton (Rivera, Lozano et al. 2009). Signalling mediated through 
both PAR receptors generates an increase of cytosolic, free Ca2+ that in turn is used by the platelet to 
increase the robustness of the functional responses enhancing platelet activation, shape change, 
secretion and aggregation. Interestingly, PAR-1 stimulation has additionally been suggested to 
activate Gαi (Kahner, Shankar et al. 2006). Thus, thrombin’s ability to initiate such a wide array of 
platelet responses via the preferential coupling of the PARs, warrants its accurate description as a 
potent platelet agonist.  
Importantly, platelets require mechanisms to control unrestrained stimulation of surface expressed 
GPCR’s that results in aggregation. Thus, their reactivity can be mediated in several ways, initiating 
endogenous paracrine signalling mechanisms and additionally the modulation of critical second 






1.12.2. Thromboxane receptor (TP)  
Adding to the complexity of platelet-endothelial signalling, EC’s have the capacity to synthesise not 
only anti-thrombotic prostaglandins such as prostacyclin (PGI2), but additionally the pro-thrombotic 
prostanoid, thromboxane A2 (TXA2) (Feletou, Cohen et al. 2010). The mechanism by which EC’s 
generate these biologically active lipids is conserved among platelets, starting with the liberation of 
arachidonic acid (A.A.) from the plasma membrane via the activation of phospholipase A2. The 
generated A.A. can then be further metabolised with the initiation of the cyclooxygenase enzymes; 
COX-1 and COX-2, resulting in the production of biologically active PGH2 (Rao and White 1985). 
Platelets and EC’s are understood to express both COX-1 and COX-2, thus they can generate PGH2, 
respectively. However, the eventual determination of prostaglandin type is mediated by the activity 
of various tissue- and cell-specific synthases. For instance, PGI2 is synthesised as the predominate 
metabolite of EC A.A. degradation, facilitated by endogenous PGI2-synthase (PGI2S) (Feletou, Cohen 
et al. 2010). Conversely, in platelets, following their activation at sites of vascular injury, A.A. is rapidly 
metabolised into TXA2 via thromboxane synthase. 
Interestingly, the generated prostaglandin is stored in platelet dense granules and thus can 
participate in the autocrine-mediated stimulation of the platelet expressed Gαq-coupled 
thromboxane receptor (TP). Similarly, in respect to PAR signal transduction, TP activation enhances 
the stimulatory pathways implicated in platelet shape change and subsequent aggregation 
(Sangkuhl, Shuldiner et al. 2011). The concomitant release of ADP and ATP from dense granules 
enhances TP stimulation. However, unlike the TP-TXA2 axis, secreted ADP acts as a potent platelet 
agonist at the platelet purinergic GPCRs, P2Y1 and P2Y12. 
 
1.12.3. P2Y1 receptor 
ADP’s contribution to platelet shape change and aggregation was first described in 1961 (Gaarder, 
Jonsen et al. 1961). Understanding of the molecular mechanisms resulting from subtype-specific 
receptor activation, remained elusive until the late 1990’s. The first purinergic receptors to be cloned, 
the P2Y1 receptor (P2Y1R) activation was shown to participate in ADP-mediated calcium mobilisation 
and subsequent platelet shape change (Jin, Daniel et al. 1998). The P2Y1 receptor has a similar 
intrinsic G-protein coupling to that of the TP receptor, Gαq. Animal studies have demonstrated that 





mobilisation and aggregation, resulting in increased bleeding times (Offermanns, Toombs et al. 
1997). Additionally, P2Y1 -/- KO mice demonstrate similar phenotypic characteristics, however they 
interestingly retain the ability to aggregate upon ADP-induced platelet activation (Stalker, Newman 
et al. 2012).  
These findings led to suggestions of an additional P2Y receptor, responsible for mediating platelet 
aggregation with mechanisms distinct to that of the coupling of P2Y1. Pharmacological studies 
followed, demonstrating concomitant activation of another receptor was required to achieve 
maximal ADP-induced aggregation. Crucially, the thienopyridine compound; clopidogrel, was shown 
to not antagonise P2Y1R (Hechler, Eckly et al. 1998). A further study demonstrating patients 
presenting with a genetic deficiency of ADP-induced platelet aggregation, revealed that their P2Y1 
gene and associated DNA and mRNA were normal, further suggesting evidence of an additional P2 
receptor with coupling to A.C (Leon, Vial et al. 1999). Previous studies had also described a patient 
with an inherited bleeding disorder with a limited and rapidly reversible platelet aggregation 
following ADP-stimulation (Nurden, Savi et al. 1995). Shortly thereafter, the molecular identity of the 
P2Y12 receptor was similarly characterised by expression cloning and ligand screening (Hollopeter, 
Jantzen et al. 2001). 
 
1.12.4. P2Y12 receptor 
The P2Y1 and P2Y12 receptors share phylogenetic and structural similarities, however they differ via 
their intrinsic G-protein coupling. The human P2Y12 GPCR consists of 342 amino acid residues and is 
assembled at the plasma membrane as 7 transmembrane-spanning alpha helices with an intracellular 
C-terminal tail parallel to that of the lipid bilayer (Figure 1.5). The extracellular N-terminus contains 
glycosylation sites that have been suggested to participate in the modulation of receptor activity 
(Cattaneo 2015). The receptor additionally contains an H-X-X-R/K motif within transmembrane 
domain (TM) 6 and extracellular loop (EL) 3, important for receptor function (Scavone, Femia et al. 
2017). This motif is highly conserved among the P2Y receptor subtypes, and believed to be a crucial 
in the extracellular recognition of nucleotides (Parravicini, Abbracchio et al. 2010). Naturally 
occurring mutations in P2Y12R structure were first described in 1992 with the observation of a patient 
presenting with life-long, excessive and prolonged bleeding times (Cattaneo, Lecchi et al. 1992). The 





2 base-pair (bp) deletion in the reading frame at position 294 of the receptor, causing a shift in the 
introduction of a stop codon, resulting in premature truncation of the protein.  
Figure 1.5. Crystal structures of the P2Y12R with agonist and antagonist binding. A) The crystal 
structure of P2Y12R showing agonist, 2MeSADP, ligand binding (3.5 Å) (Zhang, Zhang et al. 2014). B) 
The crystal structure of P2Y12R, demonstrating binding of the non-nucleotide reversible antagonist, 
AZD1283, to the receptor protein (2.6 Å) (Zhang, Zhang et al. 2014). 
More recently, studies have emerged demonstrating the importance of the cysteine residue at 
position 194 of the receptor (located within TM5) to be crucial in the binding of antagonists such as 
ticagrelor (Figure 1.5.B) (von Kügelgen, Lutz et al. 2014).  
Additional naturally occurring mutations in P2Y12R structure have been described in patients 
presenting with similar lifelong history of excessive bleeding, attributed to single nucleotide 
polymorphisms of the receptor protein, R122C. The substitution of cysteine in place of arginine at 
position 122 of the receptor has been shown to be associated with impairment of P2Y12R function. 
This substitution occurs at a site at the boundary between TM 2 and ICL 2, termed the E/DRY motif 
and is suggested to be involved in GPCR activation and G-protein coupling (Rovati and Capra 2014). 
Interestingly, the R122C mutation has additionally been shown to impair the basal constitutive 
activity of P2Y12. (Garcia, Maurel-Ribes et al. 2018). The P2Y12R has been shown to display a high 
degree of constitutive activity when overexpressed within cell based, in vitro, systems. Constitutive 





an active, signalling conformation (R*). As such, constitutively active GPCRs have increased intrinsic 
G-protein activity (Seifert and Wenzel-Seifert 2002). It has been suggested that the constitutive 
activity observed with P2Y12 may further sensitise the platelets of patients with type II diabetes 
mellitus, thus heightening their reactivity and limiting antiplatelet drug efficacy (Hu, Chang et al. 
2017).   
The P2Y12 receptor (P2Y12R) is Gαi/o-coupled, activated upon ADP ligand binding.  The resultant signal 
transduction is distinctive to that of the P2Y1-ADP axis. Receptor activation via P2Y12 initiates the 
dissociation of the Gαi/o subunit from the βγ-dimer, whereby each subunit can elicit distinct 
intracellular cascades, ultimately facilitating aggregation. 
The first arm of P2Y12 signalling begins with the Gαi/o subunit, directly inhibiting A.C. activity (Figure 
1.6.). Consequently, intracellular cAMP synthesis is suppressed (Kahner, Shankar et al. 2006). The 
signal transduction initiated serves as a brake on the PGI2-mediated cAMP synthesis, afforded by IP 
stimulation. Studies in mice lacking Gαi/o had a significantly reduced ADP-induced platelet 
aggregation (Jantzen, Milstone et al. 2001). Additionally, patients with dysfunctional P2Y12 expression 
suffer from a severe defect in A.C. inhibition and platelet aggregation. Moreover, the decrease in 
cAMP synthesis results in decreased activity of protein kinase A (PKA). PKA is responsible for a wide 
range of phosphorylation events of downstream effectors to provide an inhibitory effect on platelet 
adhesion, intracellular Ca2+ elevation, regulation of the cytoskeleton and platelet shape change 
(Wardell, Reynolds et al. 1989, Nakamura, Amieva et al. 1995, Yan, Li et al. 2009).  
The second arm of P2Y12R signalling is governed by the Gβγ heterodimer and results in the 
modulation of an array of downstream effector proteins including phosphoinositide 3-kinases (PI3K), 
protein kinase B (Akt), Rap1b, Src-family tyrosine kinases (SFKs) and inwardly rectifying G-protein 
gated potassium channels (GIRKs) (Kahner, Shankar et al. 2006). The activation of these downstream 
effectors is vital in their contribution to platelet aggregation and culminates in co-operative 
reinforcement of the robust ‘priming’; affinity modulation, and activation of the fibrinogen receptor: 
integrin αIIbβ3. 
Phosphoinositide 3-kinases (PI3K) are a group of ubiquitously expressed signal transducer enzymes, 
whereby the prominent isoforms in platelets are PI3K-γ and PI3K-β (Kahner, Shankar et al. 2006). 
Transgenic mouse platelets deficient in PI3K-γ demonstrate significantly reduced fatal 





aggregation defect resulting from impaired fibrinogen receptor activation (Jackson, Yap et al. 2004, 
Guidetti, Canobbio et al. 2015). Pharmacological inhibitor studies targeting PI3K-β revealed it 
necessary in sustaining platelet aggregation, facilitating potentiation of agonist-induced granule 
release (Jackson, Schoenwaelder et al. 2005). Interestingly, PI3K has been found to additionally 
regulate integrin αIIbβ3 adhesive bond stability, directly potentiating aggregation under high shear. 
Irrespective of the PI3K isoform activated upon P2Y12R stimulation, they subsequently activate 
additional downstream effectors; crucially the Akt isoforms, that nevertheless converge into the 
concerted activation of the small GTPase; Rap1b (Figure 1.6.). 
Protein kinase B (Akt) is a serine/threonine kinase with molecular weight of 57-kDa that becomes 
phosphorylated following ADP-induced P2Y12R stimulation, independent from P2Y1R signalling (Kim, 
Jin et al. 2004). Of the 3 isoforms known to exist in humans; Akt 1, Akt2 and Akt3, only the former; 
Akt1 and Akt2 are expressed in platelets. Their importance in platelet aggregation is suggested to 
directly modulate the function of integrin αIIbβ3 (Woulfe 2010). Both Akt isoforms utilise PIP3; the 
lipid product generated from PI3K activity, to recruit crucial adaptor proteins to the plasma 
membrane, via a conserved pleckstrin homology (PH) domain (Guidetti, Canobbio et al. 2015). The 
most abundant, and arguably the most important, being that of Rap1b.  
Subsequent downstream activation of the small GTPase from the Ras family; Rap1b, can be regulated 
directly by both PI3K isoforms. Moreover, the activation of Rab1b is understood to be further 
facilitated by guanine exchange factors (GEFs); primarily CalDAGGEFI, and GAP factor; Rasa-3. Rasa-
3 exerts an inhibitory effect on Rab1b activation, restraining CalDAGGEFI signalling and thus keeping 
the platelet in a nascent state. Moreover, it has been suggested that the signalling afforded by P2Y12R 
activation is required for the inhibition of Rasa-3, therefore enabling sustained Rap1b activation and 
consequently facilitating thrombus formation (Stefanini, Paul et al. 2015). Regardless of the source 
of activation, Rap1b is responsible for modulating the interaction between the cytosolic domain of 
integrin αIIbβ3, with the subsequent recruitment of structural proteins; talin and kindlin (Durrant, van 
den Bosch et al. 2017). Ultimately, this promotes a conformational change within the integrin, 
separating the transmembrane domains to facilitate binding of various ligands with high affinity to 
the now revealed ectodomain (Guidetti, Canobbio et al. 2015).  
Therefore, the now ‘primed’ αIIbβ3 can interact with a variety of ligands, fibrinogen, fibrin, vWF and 





soluble fibrinogen, facilitating platelet aggregation. Thus, the importance of Rap1b to this end stage 
platelet functional response is critical and reflected as such in studies of Rap1b-deficient mice 
exhibiting impaired platelet aggregation in response to ADP and additionally, Rap1b-null mice 
showing an incapability to generate occlusive thrombi utilising an in-vivo model of carotid artery 
thrombosis (Chrzanowska-Wodnicka, Smyth et al. 2005, Kahner, Shankar et al. 2006). 
Figure 1.6. P2Y12-mediated pro-thrombotic signalling elicited by endogenous agonist, ADP. Receptor 
activation with ADP causes a conformational change at the receptor level that initiates pro-
thrombotic intracellular signalling, ultimately resulting in the activation of integrin αIIbβ3, facilitating 
platelet aggregation. Illustration created with BioRender.com. 
Additionally, P2Y12-Gβγ heterodimer dissociation is understood to be implicated in the direct 
activation of membrane bound G-protein-gated inwardly rectifying potassium channels (GIRKs). The 
Gβγ-activated channels have a crucial functional role as downstream effectors following P2Y12 signal 
transduction. Their subsequent activation has been shown to contribute to the potentiation of Akt 
phosphorylation, dense granule secretion, irreversible platelet aggregation and ADP-induced TXA2 
generation (Kahner, Shankar et al. 2006, Shankar, Kahner et al. 2006). 
Due to the comprehensive array of pro-thrombotic platelet responses that can be directly elicited by 
ADP through the P2Y1 and P2Y12 signalling arms, P2Y-receptor activation is understood to be a 





role in the formation of platelet aggregates. The ability to attenuate receptor activation and hence 
platelet reactivity, has made it an attractive target for antiplatelet pharmacotherapies.  
 
1.13. Platelets and ACS pathology  
The overall contribution of platelet functional responses in ACS pathology is complex and crucial. 
Responses are influenced by the localised concentration of auto- and paracrine secreted mediators 
from their environment, both pro- and anti-thrombotic. Platelet reactivity is modulated with this 
dynamic interplay of stimulatory and inhibitory signal amplification pathways. Moreover, the source 
of the stimuli that initiate the pro-thrombotic responses of platelets, is not present in healthy vessel 
walls. Thus, the inhibitory arm of signalling afforded by the surrounding EC’s crucially keeps the 
platelets in an inactivated, quiescent state, until a time whereby their functional responses are 
needed and beneficial, i.e. - wound healing.  
However, in the context of metabolic disease that results in the formation of unstable atherosclerotic 
plaque and consequential vascular occlusion, i.e. - ACS, the need for an antiplatelet agent to 
attenuate unwanted platelet activation and crucially P2Y12-mediated aggregation, becomes 
paramount.         
 
1.14. Percutaneous coronary intervention for acute coronary syndromes 
When a patient is admitted to hospital and deemed to be suffering from an acute coronary syndrome; 
resulting from obstruction of normal coronary blood flow, percutaneous coronary intervention (PCI) 
may be performed, and is the current evidence-based standard of care within 12 hours of onset 
(Huynh, Perron et al. 2009, McCartney and Berry 2019). The procedure is carried out with the aim 
being to restore epicardial blood flow to oxygen-deprived cardiac tissue, termed reperfusion. The 
successful reperfusion of cardiac tissue is facilitated by the insertion of a stent within the artery that 
mechanically forces the occluded vessel lumen open (Dawkins, Gershlick et al. 2005). In any case, it 







1.15. Antiplatelet agents 
The current gold standard of care for patients with ACS, post-MI, is the use of dual antiplatelet 
therapy (DAPT), usually preceding percutaneous coronary intervention (PCI) and continued for up to 
12 months after the intervention. This form of treatment consists of the combinatory therapy of 
aspirin and an oral P2Y12R inhibitor. As such, the benefit of DAPT versus the sole administration of 
aspirin has been reported in numerous large scale clinical trials and laboratory studies (2001, 
Cattaneo 2004, Mauri, Kereiakes et al. 2014). This has been suggested to be due to the different 
signalling pathways that each drug targets to elicit antithrombotic efficacy. For instance, aspirin 
targets the cyclooxygenase (COX) enzymes of platelets, a known generator of inflammatory 
intermediaries (Moscardo, Santos et al. 2011). Whereas P2Y12R inhibitors selectively target the pro-
thrombotic signalling pathway initiated by P2Y12R activation (Figure 1.6). Resulting in a higher degree 




Aspirin, also known as acetylsalicylic acid (Figure 1.7.), elicits antiplatelet activity by a dose-
dependent, irreversible inhibition of COX-1. In platelets, this selective inhibition prevents the 
conversion of A.A. to PGH2 and thus, the formation of downstream TXA2 leading to reduced TP 
receptor activity (Cattaneo 2004). Aspirin functions as an antiplatelet via its ability to dampen platelet 
activation by inhibiting the amplification pathway afforded by the TP-TXA2 axis. However, due to the 
tissue distribution of the COX enzymes not being exclusive to platelets, aspirin can also inhibit the 
downstream production of anti-thrombotic PGI2 by endothelial cells (Paez Espinosa, Murad et al. 
2012). The optimal dose of aspirin in the primary prevention and management of major vascular 
events appeared controversial, until the emergence of the CURRENT-OASIS 7 trial. This demonstrated 
no difference in the risk of major bleeding complications in a head-to-head comparison of high-dose 
(>300 mg/day) and low-dose (<75-100 mg/day) aspirin (Mehta, Bassand et al. 2010).  
The ability of aspirin to effectively inhibit platelet activation has cemented itself an essential place in 
the repertoire of antiplatelet agents available to clinicians. However, the need for additional 
antiplatelet agents that have mechanisms distinct to aspirin became apparent. This is due, in part, to 





pro-thrombotic purinergic receptor, P2Y12, ultimately propagating the formation of platelet 
aggregates. Essentially, aspirin inhibits only one pathway of platelet activation whilst arguably more 
prothrombotic pathways exist. An additional drawback of aspirin alone in the prophylactic 
management of ACS is the incidence of patients allergic to the drug and moreover, the ability for 
patients to acquire aspirin resistance (Cattaneo 2004). So, despite the widespread use of aspirin, 
there became very evident drawbacks from sole administration as an antiplatelet.       
Figure 1.7. Chemical structure of acetylsalicylic acid (Aspirin). 2D-structure of aspirin, adapted to 
include compound name. PubChem identifier: CID 2244 (NCBI 2004).  
 
1.15.2. Ticlopidine and clopidogrel 
The documented antithrombotic success of ticlopidine, and later clopidogrel, heralded the potential 
of the P2Y12R pathway as a target for clinical drug development (Oestreich, Ferraris et al. 2013). 
Ticlopidine and clopidogrel belong to the thienopyridine class of antiplatelet agents, with a 
mechanism of action independent from aspirin. They both act as irreversible pharmacological 
antagonists with affinity to the P2Y12R, and are similar in structure (Fig. 1.8 & 1.9) (Maffrand 2012). 
They both reduce the pro-thrombotic signalling that results from P2Y12R activation. 
Figure 1.8. Chemical structure of ticlopidine. 2D-structure of the first generation thienopyridine, 





Indeed, clopidogrel’s predecessor, ticlopidine, emerged as the first thienopyridine indicated for the 
reduction of thrombotic events in patients with ACS (MacKenzie 1977).  However, several drawbacks 
were observed with its use. These included a high incidence of toxic effects, delayed onset of action 
and a remarkably high interindividual variability in response (Cattaneo 2006). Thus, clopidogrel 
superseded ticlopidine in the clinical setting, demonstrating a more favourable; less toxic, side effect 
profile. Clopidogrel does retain the delayed onset of action. Subsequently, a crucial study emerged 
assessing the effects of clopidogrel and aspirin coadministration. The PCI-CURE Study (Mehta, Yusuf 
et al. 2001). Interestingly, Mehta and colleagues conclude with compelling data; an overall reduction 
in cardiovascular death or myocardial infarction of 31% in clopidogrel-treated patients when 
compared to placebo-controlled. 
Figure 1.9. Chemical structure of clopidogrel and corresponding active metabolite. 2D-structures of 
clopidogrel before and following CYP450-mediated hepatic oxidation. PubChem identifier: CID 60606 
and CID 10066813, respectively.  
Despite showing promise as an effective adjunct to aspirin, and thus birthing the modern standard 
of care post-PCI; Dual antiplatelet therapy (DAPT), clopidogrel demonstrated some fundamental 
flaws that ultimately limited its therapeutic effectiveness. Like ticlopidine, clopidogrel is an oral pro-
drug requiring hepatic metabolism to produce an active metabolite effective in the antagonism of 
P2Y12R (Maffrand 2012). The existence of clopidogrel non/low responders in ~ 50% of patients, 
demonstrated a significant interindividual variability in platelet inhibition. This was governed in part 
by the relative activity of the hepatic cytochrome P450 enzyme (Storey, Wilcox et al. 2002, Cattaneo 
2004, Brandt, Close et al. 2007). Consequently, maximum inhibition of platelet reactivity is only 
reached 4-5 days after daily dosing of 75mg. Additionally, the ability for the active metabolite to 
irreversibly inhibit the P2Y12 receptor raised concerns for patients requiring coronary bypass surgery 
due to the associated increase in blood loss, reoperation for bleeding and consequent prolonged 
intensive care unit stays (Cattaneo 2006, Cattaneo 2010). Despite generating $9.4 billion in global 





underscored not only the need for new antiplatelet agents to be developed, but highlighted the true 
market value and therapeutic benefit of these drugs in modern-day cardiovascular medicine 
(Maffrand 2012). 
1.15.3. Prasugrel 
Prasugrel is a newer generation of the thienopyridine class of oral drugs and similar in structure to 
that of ticlopidine and clopidogrel (Figure 1.10) (Cattaneo 2010). Prasugrel’s conversion to the active 
metabolite, R-138727, has much less interindividual variances in hepatic metabolism when compared 
to clopidogrel (Farid, Payne et al. 2007). The reason for this variation in inhibition has been suggested 
to be due to the incidence of common loss of function polymorphisms in hepatic CYP-enzymes within 
20-40% of the patient population. Specifically, the CYP2C19 and CYP2C9 variant genotypes fail to 
metabolise clopidogrel into the active metabolite. Conversely, prasugrel becomes rapidly hydrolysed 
within the blood stream via esterases. The product formed, thiolactone, requires a single further 
oxidation step that is facilitated by any of several different CYP-isoforms, bypassing the dependency 
of CYP2C19- and CYP2C9-mediated metabolisation. Therefore, the formation of the active metabolite 
of prasugrel is subject to less interindividual variation in P2Y12R-inhibition (Brandt, Close et al. 2007). 
Consequently, the formation of the active metabolite is markedly increased in respect to that of 
clopidogrel (Payne, Li et al. 2007). Thus, prasugrel’s onset of action is more rapid. P2Y12R inhibition is 
seen within 15 minutes of dosing, producing greater mean inhibition of P2Y12-mediated platelet 
responses, at much lower loading and subsequent maintenance doses than that of clopidogrel 
(Niitsu, Jakubowski et al. 2005). 
In the randomised controlled trial, TRITON-TIMI-38; patients with ACS were treated with prasugrel 
or clopidogrel, in combination with aspirin. In summary, the study concludes a significant reduction 
in ischaemic events and stent thromboses of 27% and 57% respectively with prasugrel treatment 
versus clopidogrel (Wilcox, Iqbal et al. 2014). However, the incidence of bleeding complications in 
patients was higher in the prasugrel-treated group (13.4%) when compared to the clopidogrel-
treated group (3.2%). Thus, although showing promise as a new, more potent thienopyridine being 
more efficacious than clopidogrel, prasugrel similarly failed to address the slow offset of action 
attributed to their use, due to the irreversible inhibition of the P2Y12 receptor.   
The most underscored and untenable side effect attributed to the thienopyridines collectively, is 





turned over and new platelets are synthesised. Thus, in a clinically relevant setting whereby a patient 
with ACS may need to undergo emergency coronary artery bypass grafting surgery (CABG), the need 
for fast-acting and crucially, reversible antagonists were suggested to be preferable in these acute 
situations (Nurden and Nurden 2003, Cattaneo 2006).   
Figure 1.10. Chemical structure of prasugrel and active metabolite, R-138727. 2D-structures of 
prasugrel before and following CYP450-mediated hepatic oxidation. PubChem identifier: CID 
6918456 and CID 10405534, respectively.  
 
1.15.4. Cangrelor  
Cangrelor is a potent and direct-acting P2Y12 inhibitor, belonging to the novel nonthienopyridine ATP-
analogous group of antiplatelet agents (Figure 1.11.) (Baker and Ingram 2015). The drug is different 
to the thienopyridines, not requiring hepatic metabolism to become activated. Crucially, the drug is 
reversible (Greenbaum, Grines et al. 2006). As such, the onset of action of cangrelor is rapid; peak 
plasma concentration reached within 2 minutes following intravenous (IV) bolus, achieving platelet 
inhibition greater than 90-95%. Additionally, it has a clinical half-life of less than 5 minutes; rapidly 
deactivated by plasma esterases (Cattaneo 2010, Angiolillo, Schneider et al. 2012, Baker and Ingram 
2015).  
In a pooled analysis of three pivotal comparative efficacy studies assessing the effectiveness of 
cangrelor against either clopidogrel or placebo in PCI (CHAMPION-PCI, CHAMPION-PLATFORM and 
CHAMPION-PHOENIX), the authors report cangrelor to reduce the odds of adverse outcomes by 19% 
and stent thrombosis by 41%. Ultimately, cangrelor reduced thrombotic complications in patients 





2013). It must be noted, however, that although cangrelor clearly demonstrates superiority over the 
older thienopyridines, its use is limited largely due to its need for IV administration in peri-procedural 
situations: primarily as a bridge in treatment for patients undergoing surgery. Therefore, although 
addressing the fundamental caveats in thienopyridine treatment, cangrelor’s efficacy is limited to a 
clinical setting. Thus, failing to fill the remaining gap in the need for an orally bioavailable, direct 
acting P2Y12 inhibitor indicated for the long-term prophylactic treatment of ACS patients post-PCI.  
 
1.15.5. Ticagrelor  
Ticagrelor belongs to a new class of compounds, the cyclopentyl-triazolo-pyrimidines (Figure 1.11) 
made available to clinicians in the growing pharmacopeia of antiplatelet agents (van Giezen and 
Humphries 2005). The drug was ushered swiftly into the scientific literature, being described as a 
reversibly binding oral P2Y12R antagonist; the first of its kind (Husted and van Giezen 2009).   
Synthesised by AstraZeneca; and previously known as AZD6140, the new class of drug was shown to 
have a unique binding site, non-competitive to that for ADP (Husted and van Giezen 2009, VAN 
Giezen, Nilsson et al. 2009). Unlike the thienopyridines, ticagrelor is reported to not irreversibly bind 
to P2Y12. Therefore, there is no permanent conformational change at the receptor level that elicits 
zero intrinsic efficacy, as described by traditional drug-receptor theory of antagonism (Berg and 
Clarke 2018). Instead, ticagrelor’s pharmacology is complex. As outlined above (1.12.4), the P2Y12R 
has a high degree of agonist-independent constitutive activity. 
Elegant work from the Mundell laboratory and others indicated that ticagrelor was able to reduce 
agonist-independent receptor activity, indicating that it is an inverse agonist. In addition, ticagrelor 
demonstrates an off-target blockade of equilibrative nucleoside transporter 1 (ENT1); resulting in the 





Figure 1.11. Chemical structures of ADP, cangrelor and ticagrelor. 2D-structures of ADP, cangrelor and 
ticagrelor. PubChem identifiers: CID 6022, CID 9854012 and CID 9871419, respectively. 
The safety, efficacy and tolerability of ticagrelor was initially assessed by the DISPERSE trial (Cannon, 
Husted et al. 2007). The study involved patients with ACS, currently receiving aspirin; 75-100mg/day, 
and were switched to either ticagrelor (100mg/day) or clopidogrel (75mg/day) for 28 days. The 
authors established that ticagrelor inhibited platelet aggregation more rapidly and consistently than 
clopidogrel. However, ticagrelor did cause an increase in the incidence of moderate and minor 
bleeding that appeared dose related. Additionally, the drug was reported to cause dose-related 
adverse effects including headache, dizziness and interestingly, dyspnoea. In a sub-study of the 
DISPERSE trial (DISPERSE-2), ticagrelor use was associated with asymptomatic ventricular pauses 
(>2.5s) and additionally confirmed the increased incidence of dyspnoea (Storey, Husted et al. 2007).      
The clinical superiority and effectiveness of ticagrelor over clopidogrel was further investigated. In 
the pivotal phase III PLATelet inhibition and patient Outcomes (PLATO) trial (James, Akerblom et al. 
2009). In summary, the findings of the study were consistent with that of the TRITON-TIMI-38 study 
with ticagrelor showing greater antithrombotic efficacy over clopidogrel. However, following 
discontinuation of either ticagrelor (24-72 hours; last dose) and clopidogrel (5 days; last dose), both 
treatments exhibited similar incidences of bleeding during PCI or CABG.  
Ultimately, the data from these studies indicate clopidogrel to be a superior adjunct to aspirin post-
MI. This ushered in new guidance from the national institute of health and care excellence (NICE), 
recommending low dose ticagrelor as an adjunct with aspirin for as long as 3 years (Wise 2016). 
Ticagrelor is now described as the new gold standard of DAPT care. NICE have contraindicated the 





hepatic impairment. Thus, although addressing some of the existing limitations of the older 
thienopyridines, major bleeding and bleeding associated during emergency invasive procedures such 
as PCI, remain a pertinent clinical concern with ticagrelor, as all anti-platelet agents.  
 
1.16. Drug switching 
The rapid expansion of antiplatelet agents available to patients with ACS has enabled clinicians to 
have a greater degree of choice in tailoring treatment relevant to specific clinical scenarios. 
Therefore, it is not uncommon for switching to occur between the inhibitors and as such, concerns 
arise over the safety of the drug-drug interactions (DDIs) that may occur with their concomitant drug 
administration.  
This culminated in an international expert consensus paper, with the goal to provide guidance on 
how and when to switch therapies (Angiolillo, Rollini et al. 2017). A comprehensive guideline of 
recommendations for switching therapies has been generated, underpinned by the crucial 
pharmacodynamic characteristics attributed to each P2Y12 inhibitor. Ultimately, the modalities are 
defined broadly as: 
i) Escalation; from a less intensive to a more intensive drug (clopidogrel to ticagrelor or 
prasugrel, respectively)  
ii) De-escalation; vice versa (ticagrelor or prasugrel, to clopidogrel)  
iii) Or change; switching between two similarly efficacious agents (ticagrelor to prasugrel) (see 
Figure 1.12).  
Therefore, an accurate characterisation of the pharmacodynamics of each respective anti-platelet 
agent; mode of action, “onset” and reversibility, becomes paramount when considering their clinical 










Figure 1.12. Recommendations for switching between oral antiplatelet agents. A) Recommendations 
for switching between oral P2Y12R inhibitors in the acute/early phase of treatment (<30 days post 
index event). B) Recommendations for switching between oral P2Y12R inhibitors in the late/very late 







1.17. Research Aims  
As outlined above, the pharmacodynamics of the currently available antiplatelet agents available to 
physicians must be clearly and accurately defined for their use to be safe, and beneficial in a clinical 
setting, whereby switching between therapies is common. Therefore, the potential for DDI’s in 
respect to their concomitant administration must be considered, particularly with the newer and 
more efficacious, ticagrelor.  
The pharmacodynamics of ticagrelor are still under investigation and debate, with questions raised 
regarding the inconsistencies in reversibility of drug administration within the clinical setting (Bhatt, 
Pollack et al. 2019, Zhang, Xu et al. 2019). Thus, the aim of this thesis was to investigate two 
interrelated hypotheses to help inform this discussion. 
1) Ticagrelor, unlike other P2Y12R antagonists is an inverse agonist at the human purinoceptor, 
P2Y12, attenuating basal signalling activity.  
2) Ticagrelor is not reversible versus the endogenous P2Y12R agonist, ADP. 
To examine these hypotheses, this study consequently aims to: 
1) Further characterise ticagrelors pharmacodynamics at the receptor level, in-vitro, utilising cell 
lines and BRET2 technology.  
2) Examine the efficacy of ticagrelor administration in isolated human platelets, ex-vivo, utilising 






Chapter 2: Materials & Methodology 
 
2.1. Materials 
Name Species Description 
HEK293T Homo sapiens Transformed human embryonic kidney cells 
that express SV40 large T antigen.   
 Human platelets Homo sapiens Isolated from donated whole blood as 
described in 2.2.1.  
Table 2.1. Mammalian cell line/cell types utilised in this study.   
 
Plasmid construct  Species Gene name Concentration 
(µg/µl) 
Volume (µl) 
FLAG-P2Y12 Homo sapiens P2RY12 0.21 4.80 
Gα  Homo sapiens GNAi1 0.513 1.95 
Gβ Homo sapiens GNB1 0.65 2.30 
Gγ  Homo sapiens GNG2 0.825 1.82 
Table 2.2. Plasmid DNA constructs: species, gene name, respective concentrations and volumes 
utilised for transient cell transfection.   
 
Vector Description Source 
PcDNATM3.1 5.4 kb; Human cytomegalovirus 
immediate-early (CMV) promoter, 
neomycin resistance gene.   
ThermoFischer Scientific 








Pipettes: 1-10 µL, 20-200 µL, 200-1000 µL  Gilson  
Serological pipettes: 5 mL, 10 mL, 25 mL ThermoFischer Scientific, USA 
Cell culture dishes: 100 mm x 20 mm Corning, Germany  
Centrifugation vials: 10 mL ThermoFischer Scientific, USA 
96-well cell plates Greiner bio-one, Austria 
Falcon tubes:  15 mL, 50 mL  BD biosciences 
Eppendorf tubes: 0.5 mL, 1.5 mL, 2 mL   Eppendorf 
Pipette controller: Pipetboy 2 Integra 
Syringes/Hypodermic needles BD biosciences 
Pipette tips: 10 µL, 200 µL, 1000 µL Corning/Rainin/STARLAB 
Table 2.4. Laboratory consumables and their supplier.  
 
Table 2.5. Compounds utilised in this study, their description and supplier.  
Compound Description Supplier 
Ticagrelor P2Y12R antagonist AstraZeneca, Sweden 
AR-C66096 tetrasodium salt 
(clopidogrel active metabolite) 
P2Y12R antagonist Tocris, UK 
Cangrelor P2Y12R antagonist Tocris, UK 
R-138727 (prasugrel active 
metabolite) 
P2Y12R antagonist Sigma-Aldrich, UK  
Xanthine amine congener (XAC) Non-selective adenosine 
receptor antagonist 
Tocris, UK 
Adenosine 5’- diphosphate (ADP) P2Y1/12R agonist Sigma-Aldrich, UK 
U46619 TP receptor agonist Tocris, UK 
Dimethyl Sulfoxide (DMSO) Aprotic solvent  Sigma-Aldrich, UK 
Forskolin Direct stimulator of 






Table 2.6. Reagents used in this study, their description and supplier.  
  
Reagent Description Supplier 
Apyrase Enzyme catalysing the 
hydrolysis of ATP, yielding 
AMP and organic phosphate 
Sigma-Aldrich, UK 
Penicillin Antibiotic for the prevention 
of bacterial contamination 
Gibco 
Streptomycin  Antibiotic for the prevention 





LipofectamineTM 2000  Transfection reagent ThermoFischer Scientific, USA 
Coelenterazine 400a Luciferin; substrate for 
Renilla reniformis (RLuc) 
InSight Biotechnology, UK 
Trypsin-EDTA Cell-dissociation reagent Gibco 
Acid citrate dextrose (ACD) Blood anti-coagulant  BioSight Ltd, Israel 
Ethanol  Solvent Honeywell, UK 
Dulbecco’s modified eagle 
medium (DMEM) 
Synthetic cell culture 
medium for the maintenance 
and proliferation of cells   
Sigma-Aldrich, UK 
Tyrode’s HEPES buffer Isotonic buffer solution; pH 
7.3 




Isotonic buffer solution; pH 
7.4 
Sigma-Aldrich, UK 
Opti-MEM reduced serum 
media 
Cell culture medium for 






2.2.  Methodology 
 
2.2.1. Human platelet isolation  
Human blood was donated by healthy, consenting volunteers in accordance with the University of 
Bristol’s Ethics of Research Policy and Procedure, adhering to and aligning with the WMA Declaration 
of Helsinki.   
Donation of human blood was performed via venipuncture, with the use of a butterfly needle affixed 
to a 50 mL BD Plastipak ™ syringe that was pre-filled with 10% sodium citrate.  The collected blood 
was dispensed equally into LP4 tubes (Appleton Woods, UK), sealed and centrifuged at 161 x g for 17 
minutes (Heraeus Megafuge, ThermoFisher Scientific), consequently isolating platelet-rich plasma 
(PRP). Isolated PRP was then collected and dispensed into a 15 mL Falcon tube (Corning, Germany), 
where the addition of 0.02 U/mL apyrase and 10 µM indomethacin was included. Following this, the 
determination of platelet density was calculated utilising the Z1 Coulter particle counter (Beckman 
Coulter, UK), and platelet concentration was adjusted to 4x108/ml. The PRP-containing falcon tube 
was incubated via water bath at 30°C for 30 minutes prior to the commencement of light 
transmission aggregometry (LTA) experiments (Figure 2.1. 1-4).  
Remaining blood within the LP4 tubes were centrifuged once more at 465 x g for 10 minutes to 
separate the platelet-poor plasma (PPP) from the remaining blood constituents.  PPP was then 
collected and transferred to a 1.5 mL Eppendorf tube and further centrifuged at 161 x g for 5 minutes, 
and the supernatant collected. Whilst collecting the centrifuged PPP supernatant, care was taken not 
to aspirate any pelleted blood constituents that may have formed following the centrifugation.  240 
µL of PPP was dispensed into a 450µL P/N 312 cuvette (Chrono-log corporation) and subsequently 
diluted with 60 µL of HEPES Tyrode’s buffer to make a total volume of 300 µL. This resulting cuvette 
of diluted PPP was then used as the optical density reference value with respect to unstimulated PRP, 
due to the lack of aggregatory response resulting from the absence of platelets in PPP following 







2.2.2. Light transmission aggregometry (LTA)   
To investigate the inhibitory effect of ticagrelor on the functional response of platelet aggregation 
following stimulation with ADP, light transmission aggregometry experiments were performed 
utilising an optical lumi-aggregometer (Chrono-log model 700, Chrono-log Corporation). Light 
transmission aggregometry is a widely utilised diagnostic tool to assess platelet function ex-vivo and 
facilitates the evaluation of anti-platelet therapy efficacy (Hvas and Favaloro 2017).  
PRP was dispensed into consecutive P/N 312 cuvettes (Chrono-log corporation) (Fig 2.1. 5-6) where 
reactions were performed within a total final volume of 300 µL. The inclusion of a stirring bar within 
each PRP-containing cuvette was mandatory; with an angular speed of 161 x g, indicative of high 
shear stress conditions resulting from laminar flow within vasculature. 30 µL of 100 µM 
inhibitor/antagonist (10 µM) was added to 240 µL of unstimulated PRP and allowed to incubate for 
2 minutes within the heated optical reading chamber, at 37°C. Once in place, warmed PRP-containing 
cuvettes within the lumi-aggregometer were baselined with respect to the PPP-containing cuvette. 
Following the elapsed incubation time of the antagonist, 30 µL of 100 µM ADP (10 µM) was included, 
stimulating the platelets. Immediately after the addition of the agonist, measurements were started 
within the Aggrolink8 software, recording aggregation (%) with respect to time (mins) (Figure 2.1. 5-






Figure 2.1. Human platelet isolation & light transmission aggregometry. Simplified illustration of 
platelet isolation (1-4) followed by light transmission aggregometry (5 & 6). Illustration constructed 
in BioRender.com. 
 
2.2.3. Sterilisation   
Where appropriate, lab consumables were sterilised by autoclave at 120°C. Where autoclaving was 
not deemed appropriate; for buffers and media, sterilisation was performed by filtration with the 
use of a 250 mL vacuum filter bottle system, 0.22µm pore (Corning, Germany). Mammalian cell 
culture methods were performed under strict aseptic technique, within a fume hood that was 
sterilised with 70% ethanol before and after use.  
2.2.4. Mammalian cell culture  
HEK293T cells were maintained in a humidified incubator, supplemented with 95% O2 and 5% CO2 at 
37°C.  The proliferation of cells was done so in 100 mm x 20 mm dishes (Corning, Germany) with 
Dulbecco’s Modified Eagle medium (DMEM); supplemented with 10% foetal bovine serum (FBS), 2 





Cell confluency was assessed via tabletop microscope (Nikon, UK), where approximately 90% 
coverage was determined to be ready for cell passage. Spent media was aspirated and removed from 
the 100 mm x 20 mm dishes and 3 mL of PBS was subsequently dispensed to the inside wall, with the 
intention to wash the cells whilst minimising their disruption. Following the washing of cells, spent 
PBS was subsequently aspirated and discarded.  1 mL of pre-warmed trypsin-EDTA was introduced 
directly to the cells, and the 100 mm x 20 mm dish subsequently incubated in humidified conditions 
at 37°C for 2 minutes, facilitating the dissociation of cells.  Following the elapsed 2-minute incubation, 
care was taken to ensure that the cells were sufficiently detached from the dish in which they were 
contained. After this determination of successful detachment of cells, 3 mL of pre-warmed DMEM 
was introduced, inactivating any aberrant trypsin activity. Detached cells were then homogenised 
within the introduced DMEM, creating a cell suspension that was subsequently transferred to a 10 
mL vial and centrifuged at 161 x g for 3 minutes.   
Care was taken to ensure that the cell pellet that formed upon centrifugation was left undisturbed 
whilst aspirating and discarding the supernatant. Following this, 1 mL of additional pre-warmed 
DMEM was introduced and the cell pellet subsequently re-suspended. Appropriate volumes of this 
cell suspension were then used to determine the extent of time taken to reach 100% confluency of 
the next passage. Fresh 100 mm x 20 mm dishes were prepared and 9 mL fresh DMEM dispensed 
into each, respectively. The re-suspended cells were then dispensed into to the new DMEM-
containing dishes, according to the volume deemed appropriate. For example, 500 - 600 µL of the 
cell suspension added to a new 100 mm x 20 mm dish; containing 9 mL fresh complete media 
(DMEM), was determined to be 1:2 in respect to the original 1000 µL cell suspension. The new dish 
was subsequently incubated in humidified conditions at 37°C, supplemented with 95% O2 and 5% 
CO2. The maintenance and passage of HEK293T cells was performed regularly, generating a constant 
supply of cells suitable for efficient transient transfection with our receptor of interest, P2Y12 and 
associated G-proteins. 100 mm x 20 mm dishes that were seeded 1:2 was deemed ready for transient 
transfection the following day.  
2.2.5. Transient cell transfection  
Transient cell transfection is a widely utilised technique in mammalian cell culture, facilitating the 
integration of foreign genetic material into the target cell; in this study, the HEK293T. This method 





suitable for pharmacological and preclinical studies; FLAG-P2Y12R, Gα, Gβ and Gγ (Table2.2.) (de Los 
Milagros Bassani Molinas, Beer et al. 2014).   
Cell confluency was observed under tabletop microscope (Nikon, UK) whereby approximately 70-
90% confluency was determined to be optimal for transient cell transfection.    
Following the determination of optimal cell confluency, 2 x 1.5 mL Eppendorf tubes were set aside 
for each respective 100 mm x 20 mm dish to be transfected.  500 µL of pre-warmed Opti-MEM® I 
Reduced-Serum media was subsequently dispensed into each Eppendorf tube.  Plasmid constructs 
were dispensed into one of the Eppendorf tubes at volumes and concentrations as indicated by Table 
2.2. Within the remaining Opti-MEM containing Eppendorf tube, LipofectamineTM 2000 transfection 
reagent was included at a ratio of 2:1, in respect to Lipofectamine: DNA, and incubated for 5 minutes 
at room temperature. For example, FLAG-P2Y12 and G-protein constructs included were 5 µg, 
therefore Lipofectamine was added (10 µL) giving 2:1. Subsequent to the elapsed 5-minutes at room 
temperature, the contents of the lipofectamine containing Eppendorf tube were combined with the 
DNA construct-containing Eppendorf tube, and incubated at room temperature for a further 20 
minutes.  
Following the 20 minutes at room temperature, 100 mm x 20 mm cell dishes determined to be 
optimal for transfection were aspirated of spent media and cells were subsequently washed with 3 
mL of sterilised (PBS) (GIBCO), taking care to minimise disruption to the cell monolayer.  Following 
washing, spent PBS was aspirated and 5 mL of warmed Opti-MEM® I Reduced-Serum media was 
added to each dish, respectively. The lipofectamine & DNA construct-containing Eppendorf was 
dispensed into the respective dish, in a  drop-wise fashion; taking care to ensure sufficient coverage, 
and subsequently incubated at 37 °C in humidified conditions (95% O2 & 5% CO2) for 5-6 hours to 
allow lipofectamine/DNA complexes to form. Subsequently, spent Opti-MEM® was aspirated and 8 
mL of DMEM complete media; supplemented with FBS and pen/strep, was dispensed into each 
respective 100 mm x 20 mm dish. Cell dishes were then labelled either pcDNA or FLAG-P2Y12, 
corresponding to the respective transfection, in addition to the cell’s passage number.  Dishes were 
then allowed to incubate at 37°C in a humidified atmosphere (95% O2 & 5% CO2) for approximately 
48 hours. Following this, the bioluminescence resonance energy transfer (BRET2) assay was ready to 






2.2.6. Bioluminescence Resonance Energy Transfer (BRET2) 
Bioluminescence Resonance Energy Transfer (BRET2) is a widely utilised in-vitro technique within the 
field of molecular biology. It facilitates the monitoring of real time protein-protein interactions via 
the resonance energy transfer between a bioluminescent donor protein; Renilla luciferase (RLucII), 
and a fluorescent acceptor protein; green fluorescent protein (GFP) (Figure 2.2.) (Xie, Soutto et al. 
2011).  
In this study, the transient transfection of P2Y12 and complementary G-proteins enabled their 
successful synthesis and expression at the HEK293T cell membrane. Moreover, RLucII was fused to 
the Gα subunit, and GFP fused to Gγ. Following their successful expression and recombination, the 
G-proteins exist as a heterodimer. Therefore, the distance between the protein subunits gives a valid 
indication of receptor activation following agonist treatment, or conversely inactivation following 
antagonist administration. A distance greater than 10 nm between the donor protein and acceptor 
fluorophore corresponds to receptor activation, indicating a protein-protein interaction that 
consequently emits green light. Conversely, a distance <10 nm corresponds to receptor inactivation, 
indicating an absence of interaction, emitting blue light (Figure 2.2.). Thus, the BRET2 assay facilitates 
the pharmacodynamic assessment of antiplatelet therapeutics in respect to P2Y12, at the receptor 
level. Ultimately, stimulating P2Y12 causes a decrease in the BRET signal, indicating the dissociation 
of the G-protein subunits.     
All BRET2 experiments were performed approximately 48 hours following the transient cell 
transfection as previously described in 2.2.5.   
Spent DMEM media was aspirated from the 100 mm x 20 mm dishes containing the transiently 
transfected HEK293T cells, and 2-3 ml of sterilised PBS was subsequently dispensed into each plate 
with the intention of washing the cells.  1 mL of pre-warmed 0.05% trypsin-EDTA was dispensed 
directly to the cells and incubated for 2-3 minutes to dissociate and detach them from their 
respective dishes. After this incubation time elapsed, 3 mL of phenol-free DMEM supplemented with 
10% FBS and 2mM glutamine was dispensed into the cell dish, inactivating the trypsin. Cells were 
then homogenised into suspension and transferred to a 10 mL centrifugation vial. Centrifugation of 
the cells followed at 161 x g for 3 minutes at room temperature. Subsequently, the supernatant was 
aspirated, and care was taken to leave the cell pellet that formed, undisturbed. An additional 3 mL 





to suspend the cells in the media.  Centrifugation was of the homogenised cells was performed again, 
at 161 x g for 3 minutes at room temperature, and the supernatant discarded.  
The cell pellet was resuspended in 1 ml phenol-free DMEM, and a further 9 ml was dispensed into 
the vial to give a final volume of cell suspension of 10 ml. Cells were subsequently counted under 
microscope via haemocytometer (Reichert, USA) and their concentration in suspension was adjusted 
such that 80 µl of the suspension, seeded into each well of a 96-well white flat bottom microplate 
(Grenier Bio-One, Austria), yielded approximately 1x105 cells/well. The 96-well plate was then placed 
into an incubator at 37°C in a humidified atmosphere (95% O2 & 5% CO2) and allowed to rest whilst 
the preparation of drugs was completed.  
Drug dilutions were done so within 0.5 ml Eppendorf tubes, and serial dilutions carried out where 
appropriate in respect to the aims of the experiment performed. Once dilutions were prepared, 
appropriate volumes of each drug concentration and vehicle (>50 µL) were seeded into a 96-well 
transparent flat bottom plate (Grenier Bio-One, Austria), and labelled accordingly. Following this, the 
drug-containing transparent 96-well plate was covered and stored within a refrigerator at 4°C, to 
minimise any degradation whilst the RLucII substrate was prepared.  
The substrate: coelenterazine 400a, is light-sensitive and thus care was taken to ensure the aliquots 
in which it was prepared and stored in, was covered with aluminium foil to mitigate degradation. 
Coelenterazine 400a aliquots, stored at -20°C, had a stock concentration of 500 mM in a volume of 
150 µl. Thus, 1.35 ml of phenol-free DMEM medium was introduced into the coelenterazine-
containing Eppendorf, generating a working concentration of the substrate of 50 mM. The BRET2 
assay was then ready to be performed.   
The 96-well cell-seeded plate was placed into the tray of the FLUOstar® Omega plate reader (BMG 
Labtech, UK), its heating block set to a temperature of 37°C and the injection system thoroughly 
cleaned with 70% ethanol, followed by rinsing with ddH2O. Once cleaned, the prepared 
coelenterazine 400a substrate was subsequently primed within the injector system, and delta-BRET 
measurements were ready to be recorded. The appropriate treatment and incubation of an 
agonist/antagonist to the desired wells of the 96-well cell-containing plate was performed prior to 
the measurement of the luminescence and fluorescence signal emitted, according to the aims of the 





The spectrofluorometer instrument of the plate reader was prepared such that the bioluminescence 
emission was collected with a dedicated filter at a wavelength of 410-480 nm for RLucII, and the 
fluorescence emission concurrently collected utilising a filter set to 515-530 nm for GFP.  
Consequently, the data collected was calculated to give a BRET ratio as indicated by the equation 




The equation above calculates the ratio of the GFP channel signal and the RLucII channel signal of 
cells that were untreated, giving a basal signal. This BRET ratio is then utilised in the equation below 
to determine the change in the basal BRET signal when the same cells were independently treated 
with agonist/antagonist (ΔBRET): 
 
        
 
The equation above is an example of how the ΔBRET values were calculated for vehicle-control 
treated cells (DMSO 0.1%, or PBS). This process of calculating ΔBRET values was repeated with cells 
that were treated with agonist/antagonist, producing changes in the basal BRET signal in respect to 
the BRET ratio measured from untreated cells. Therefore, ΔBRET is the difference in the BRET signal 
measured between cells treated with agonist/antagonist, subtracted from the BRET signal measured 
from cells treated with the respective vehicle.                   
BRET ratio  =  GFP channel signal of untreated cells        
Luminescence (RlucII) channel signal 
of untreated cells 
            
=   A 
ΔBRET  =   
            
A      –      GFP channel signal of vehicle-only treated cells 
                  RLucII channel signal of vehicle-only treated cells 





Figure 2.2. BRET2 assay. Simplified illustration depicting the molecular basis of protein-protein 
interactions governed by the BRET2 assay at the receptor level. RLucII catalyses the breakdown of 
coelenterazine 400a to coelenteramide in the presence of oxygen, emitting green light and indicating 
receptor inactivation/stabilisation. In situations of receptor activation, whereby RLucII and GFP are 
separated by a distance >10 nm, resonance energy transfer between donor and acceptor proteins is 
not facilitated, thus blue light is emitted. The BRET signal is measured as this ratio of green to blue 






2.2.7. Statistics    
All statistical analyses were performed utilising GraphPad Prism version 8.0.0 for Windows, GraphPad 
software, San Diego, California USA, www.graphpad.com. Where applicable, data represent the 
mean + SEM of at least 3 independent experiments, unless otherwise indicated by text.  
Concentration-response curves were fitted with non-linear regression and a non-variable slope to 
generate EC50 values for the agonists, indicating the concentration required to produce 50% of the 
maximal response. Significant differences in the mean delta-BRET signal obtained upon agonist or 
antagonist treatment were analysed using a one- or two-way ANOVA, with Bonferroni, Tukey’s or 
Sidak’s multiple comparisons post-hoc tests applied where appropriate, as indicated by text. ANOVA 
was employed to establish statistical differences between the means of three or more independent 
groups. In this study, ANOVA was determined to be appropriate and post-hoc tests employed to 
control the experimental-wise error rate when making pairwise comparisons. In all instances, P 
values < 0.05 were considered significant. * = P < 0.05, ** = P < 0.01, *** = P < 0.001, **** = P < 
0.0001, ns = P > 0.05.     
Chapter 3: Results 
Ticagrelor has been shown to be clinically superior to many previously described antiplatelet agents. 
Importantly it is classified as the only orally active and reversibly binding P2Y12R antagonist (Husted 
and van Giezen 2009, Wise 2016). A possible reason for the markedly increased efficacy of ticagrelor 
in respect to the previously described antiplatelet agents may be attributed to novel mechanisms of 
action. This novel mode of action emanates from the discovery of the basal constitutive activity of 
the P2Y12R receptor and that ticagrelor may act as an inverse agonist at this receptor (Aungraheeta, 
Conibear et al. 2016). The main aim of this study is to further characterise the pharmacodynamics of 
ticagrelor in both cell lines and human platelets. To address these aims, two main techniques are 
employed as described in 1.17. The first, in cell lines utilises bioluminescence resonance energy 
transfer (BRET2) to assess agonist and antagonist-dependent effects on P2Y12R activity at the 
receptor-G-protein level. The second, in human platelets, uses light transmission aggregometry (LTA) 







3.1. Characterisation of the pharmacodynamics of ticagrelor antiplatelet therapy at 
the human P2Y12R utilising BRET2 technology. 
BRET2 is a pharmacological technique that facilitates the real-time assessment of protein-protein 
interactions within cell-based systems (Xie, Soutto et al. 2011). Following the transient transfection 
of protein constructs as described in 2.2.5., successful recombination of P2Y12 and associated G-
proteins at the cell surface allows the monitoring of the coupling of the G-protein subunits to the 
receptor upon agonist/antagonist administration. In the resting state of the receptor, the G-protein 
subunits; Gαi and Gβγ are associated in proximity. As described in 2.2.6., the energy donor molecule; 
RLucII is fused to the Gαi subunit (GNAi1-RLucII) and the acceptor molecule; GFP10 is fused to the Gγ 
subunit of the Gβγ heterodimer (GNG2-GFP10). Upon receptor activation, GNAi1-RLucII and GNG2-
GFP10 dissociate. The movement of these subunits to a distance greater than 10 nm apart causes 
RLucII to emit blue light with a wavelength of 410-480 nm, indicating no protein-protein interaction 
(Figure 2.2.). Conversely, upon receptor inactivation, GNAi1-RLucII and GNG2-GFP10 associate to 
facilitate transfer of resonance energy from RLucII to GFP10, with GFP10 emitting green light at a 
wavelength of 515-530 nm, indicating protein-protein interaction (Figure 2.2.).  
Therefore, an increase in the BRET signal correlates to G-protein association and is hence interpreted 
as receptor inactivation/stabilisation. Conversely, a decrease in the BRET signal correlates to G-





3.1.1. Concentration-dependence of agonist-induced P2Y12R activity.  
Incubation of transiently transfected HEK293T cells, as outlined above, with varying concentrations 
of ADP was performed to assess the concentration-dependence of agonist-induced P2Y12R activity. 
5-minute incubations of varying concentration of ADP caused significant decreases in corresponding 
delta-BRET values respectively (Figure 3.1.B). To determine an appropriate concentration of agonist 
to utilise in further BRET2 experiments, the EC50 value for ADP was calculated and a suitable sub-
maximal concentration of ADP chosen (10 µM). To assess if the agonist induced P2Y12 activity 
changed with respect to time, BRET2 time course assays were designed and employed (Figure 3.1.A). 
Figure 3.1.A indicates that 10 µM ADP caused a decrease in BRET signal that occurred rapidly, 
indicating a sub-maximal response achieved between 5-10 minutes that was sustained until the 60-
minute mark. This incubation time of ADP (10 µM; 5 mins) was deemed sufficient to evoke a 
submaximal response of P2Y12R activation and was thus employed in subsequent BRET2 assays.  
Figure 3.1. Time-course and concentration-dependence of P2Y12R activation with ADP.  (A) HEK293T 
cells, transiently transfected with P2Y12R and associated G-proteins, were incubated with ADP (10 
µM, 60 minutes) and delta-BRET measurements were taken immediately after each respective 
elapsed time point, generating a time course of ADP administration. (B) Transfected cells were 
incubated with varying concentrations of ADP (0.1 nM - 10 µM) for 5 minutes. Immediately after this 
elapsed incubation time, delta-BRET measurements were taken for each corresponding 
concentration, thus generating a dose-response curve for ADP. Data plotted represents the change 





3.1.2. Inhibition of ADP-induced P2Y12R activity by a range of antiplatelet agents. 
As seen in Figure 3.1., ADP administration causes a concentration-dependent decrease in the BRET-
signal that is indicative of receptor activation. To assess the efficacy of ticagrelor and previously 
described antiplatelet agents on the modulation of receptor stabilisation/inactivation, transfected 
HEK293T cells were incubated with antagonist (10 µM) for 7 minutes, followed by stimulation with 
ADP (10 µM) for a further 3 minutes (Figure 3.2B). Stimulation of ticagrelor treated cells with 10 µM 
ADP caused a significant decrease and reversal of the BRET-signal obtained by ticagrelor 
administration alone (10 µM). Similarly, stimulation of cangrelor-treated cells with ADP (10 µM) 
caused a decrease in the BRET-signal with respect to cangrelor administration alone. Further, AR-
C66096 and R-138727 both similarly ablate the ADP-response with their respective concomitant 
administration with the agonist. Taken together, these data indicate the relative efficacies of each 
antiplatelet agent in respect to their antagonism of receptor activation. In summary, the data 
displayed in figure 3.2. confirms the utility of the antagonists to ablate ADP-induced P2Y12R activity. 
Figure 3.2. Antagonism of ADP-stimulated P2Y12R activity by pre-treatment with a range of P2Y12R 
inhibitors.  HEK293T cells were transiently transfected with P2Y12R and associated G-proteins as 
indicated in 2.2.5. (A) Cells were treated with antagonists (10 µM) for 10 minutes and measurements 
were taken immediately after the elapsed time, generating mean delta-BRET values for each 
respective P2Y12R inhibitor. (B) Cells were pre-treated with antagonist (10 µM) for 7 minutes, 
followed by treatment with ADP (10 µM) for a further 3 mins and delta-BRET measurements taken 
immediately following a total elapsed time of 10 minutes. Significant differences between mean 
delta-BRET values were analysed via one-way ANOVA with Sidak’s multiple comparisons post-hoc 
test. Data plotted represent the mean + SEM, n = 3. ns = P > 0.05, **** = P < 0.0001. (A) Pairwise 





3.1.3. Assessment of the onset and duration of inverse agonist activity at the P2Y12R. 
Previous research emanating from the Mundell laboratory has shown ticagrelor to exhibit inverse 
agonist activity at the P2Y12R (Aungraheeta, Conibear et al. 2016). As shown previously in figure 
3.2., ticagrelor and cangrelor effectively ablate ADP-mediated P2Y12R activation. 
To assess whether the inverse agonist action of P2Y12R activity with ticagrelor and cangrelor was 
time-dependent, time course assays were subsequently employed as shown in Figure 3.3. Transiently 
transfected HEK293T cells were incubated with ticagrelor (10 µM) or cangrelor (10 µM), and delta-
BRET measurements taken immediately following the elapsed incubation times (Figure 3.3.).  
Ticagrelor administration caused a marked increase in the BRET-signal that was sustained for the 
duration of the assay (60 mins). Cangrelor administration similarly caused an increase in the BRET-
signal that was sustained until the 25-minute mark. In summary, this data facilitated the 
determination of optimal incubation times of both inhibitors for subsequent experiments, and to 
additionally provide insight into the speed of onset of action of both antiplatelet therapies.  
Figure 3.3. Time-course assays of ticagrelor and cangrelor. HEK293T cells, transiently transfected with 
P2Y12R and associated G-proteins, were incubated with either ticagrelor (10 µM) (A) or cangrelor (10 
µM) (B) for a total of 60 minutes. Delta-BRET measurements were taken immediately upon reaching 
respective elapsed time points, generating time courses of ticagrelor (A) and cangrelor (B) 






3.1.4. Concentration-dependence of ticagrelor and cangrelor inverse agonist activity 
at the P2Y12R. 
To assess whether the inhibition elicited by ticagrelor and cangrelor displayed concentration-
dependence, dose-response relationships were subsequently constructed (figure 3.4). Incubation of 
transiently transfected HEK293T cells with varying concentrations of ADP produced an agonist-
mediated response of receptor activation, consequently generating an EC50 value of 141 nM. 
Ticagrelor and cangrelor administration caused a concentration-dependent inhibition of basal 
receptor activity. With EC50 values of 208 nM and 62 nM, respectively. The data shown in figure 3.4. 
demonstrate ticagrelor and cangrelor to both behave as inverse agonists at the P2Y12R. Intriguingly, 
cangrelor appears to behave as a partial inverse agonist with a reduced Emax, whereas ticagrelor a 
full inverse agonist (Berg and Clarke 2018). Cangrelor exhibits higher potency than that of ticagrelor, 
aligning with data from previous studies (Garcia, Maurel-Ribes et al. 2018).  
Figure 3.4. Concentration-dependence of Ticagrelor, Cangrelor and ADP.  HEK293T cells, transiently 
transfected with P2Y12R and associated G-proteins, were incubated with varying concentrations of 
either ticagrelor, cangrelor or ADP for 5 minutes. Delta-BRET measurements were taken immediately 
after the elapsed incubation time. Data plotted represent the change in BRET ratio upon agonist or 
antagonist treatment, displayed as mean ± SEM of at least 4 independent experiments. Ticagrelor 
EC50 value = 208 nM (70 – 587 nM, n = 4). Cangrelor EC50 value = 62 nM (33 – 117 nM, n = 5). ADP 






3.1.5. Mode of action of ticagrelor.   
The mechanism of action of ticagrelor has previously been suggested to be distinct from that of 
previously described antiplatelet agents (VAN Giezen, Nilsson et al. 2009, Dobesh and Oestreich 
2014). Ticagrelor has been shown to inhibit the adenosine transporter ENT1; resulting in the 
accumulation of extracellular adenosine (Aungraheeta, Conibear et al. 2016). Additionally, off target 
effects of dyspnoea with ticagrelor use have been reported in a concentration-dependent manner 
(Cannon, Husted et al. 2007), potentially related to this increase in plasma adenosine levels.  
Experiments were designed to further characterise of the mode of action of ticagrelor (Figure 3.5.). 
We first tested if the accumulation of extracellular nucleotides, including ADP, in our cell line system 
may affect the basal constitutive activity of P2Y12R and therefore ticagrelor action. Transiently 
transfected HEK293T cells were incubated with apyrase (0.2 U/mL; 30 minutes) in Figure 3.5.A. No 
significant differences were observed in the BRET-signal achieved by ticagrelor in the absence or 
presence of apyrase (ns = P = 0.8671, n = 3). Any accumulation of extracellular nucleotides did not 
affect the level of inhibition elicited by ticagrelor at the P2Y12R. 
As previously described in 1.12., potential breakdown of extracellular nucleotides via CD39 results in 
the generation of extracellular adenosine. Potentially through the inhibition of ENT1 transporters, 
ticagrelor could lead to accumulation of extracellular adenosine that in turn could activate A2B 
adenosine, Gαs-coupled receptor signalling (Mundell, Loudon et al. 1999). Transiently transfected 
HEK293T cells were therefore pre-treated with xanthine amine congener (XAC); a non-specific 
adenosine receptor antagonist (10 µM; 30 minutes) (Figure 3.5.B). No significant differences were 
observed in the BRET-signal achieved by ticagrelor in the presence and absence of XAC (ns = P = 
0.4893, n = 3). Therefore, adenosine receptor blockade had no effect on ticagrelor activity in this cell 
line.  
Previous studies have indicated that intracellular cAMP levels increase in cells following ticagrelor 
treatment in part through the increased extracellular adenosine levels described above. To further 
characterise if increased levels of cAMP could modulate ticagrelor activity, cells were incubated with 
forskolin (10 µM; 30 minutes) to directly stimulate adenylyl cyclase activity (Figure 3.5.C). No 
significant differences were observed in the BRET-signal achieved by ticagrelor administration alone 
and the concomitant administration of ticagrelor + forskolin (ns = P = 0.3289, n = 3). Therefore, 





Another important control experiment was undertaken in HEK293T cells, transiently transfected with 
µ-opioid receptor (MOR) and associated G-proteins. The MOR is like P2Y12R; Gαi-coupled. 
Transfected cells were incubated with the MOR agonist DAMGO (10 µM), ticagrelor (10 µM) or both 
(Figure 3.5.D). The MOR is similarly Gαi-coupled in respect to P2Y12R, however concomitant ticagrelor 
+ DAMGO administration in these transfected cells does not produce a significant difference in delta-
BRET value as seen with DAMGO incubation alone (ns = P > 0.9999, n = 3). Therefore, the inhibitory 
effect of ticagrelor upon G protein-dissociation is dependent upon the expression of the P2Y12R and 
associated G-proteins.  
Figure 3.5. Probing the mechanism of action of ticagrelor.  HEK293T cells, transiently transfected with 
P2Y12 and associated G-proteins were incubated with apyrase (0.2 U/ml) (A), XAC (10 µM) (B) or 
forskolin (10 µM) (C) for 30 minutes, followed by ticagrelor (10 µM) for 5 minutes. HEK293T cells, 
transiently transfected with the µ-opioid receptor and associated G-proteins were incubated with 
DAMGO (10 µM) (D) for 15 minutes, followed by ticagrelor (10 µM) for 5 minutes. Upon reaching the 
elapsed incubation times, delta-BRET measurements were taken immediately, and data plotted 
represent the mean + SEM, n = 3. Significant differences between conditions were analysed via one-





transfection of HEK293T cells with the µ-opioid receptor and associated G-proteins (Fig 3.5.D) was 
kindly performed by Yahia Alghazwani, Henderson & Kelly Laboratory.  
Taken together, the above experiments provide confidence that the inverse agonist utility of 
ticagrelor is indeed observed at the human P2Y12R. Additional experiments were subsequently 





3.1.6. Evaluation of ticagrelor’s binding modality 
The binding modality of ticagrelor is currently still under debate (VAN Giezen, Nilsson et al. 2009, 
Hoffmann, Lutz et al. 2014, Garcia, Maurel-Ribes et al. 2018). Previous mutagenesis studies have 
suggested the cysteine residue at position 194 (C194) of the receptor protein to be important for the 
recognition of ticagrelor’s antagonist activity (Hoffmann, Lutz et al. 2014). Therefore, we employed 
mutagenesis experiments to assess these conclusions (Figure 3.6. & Figure 3.7.). HEK293T cells 
expressing wild-type or mutant P2Y12R (C194A) were treated with a range of previously described 
antiplatelet agents or ADP to assess the affect, if any, of the mutated receptor on the function of the 
respective agents. 
As seen below in Figure 3.6.A., the C194A mutation produced a statistically significant reduction in 
mean delta-BRET values elicited by ticagrelor administration alone [orange and blue bars (**** = P < 
0.0001, n = 3)]. Additionally, the mutation produced a statistically significant reduction in the ability 
of ticagrelor to inhibit ADP-stimulated P2Y12R activity [brown and purple bars (**** = P < 0.0001, n = 
3)].  Notably, ADP-stimulated activity was unaffected by the C194A mutation. Further, the mutation 
had no effect on cangrelor inverse-agonist activity or cangrelor-dependent inhibition of ADP-
stimulated P2Y12R activity (Figure 3.6.B). Similarly, the C194A mutation had no effect on AR-C66096-
dependent antagonism of ADP-stimulated P2Y12R activity (Figure 3.6.C) (ns = P > 0.05, n = 3).  
Therefore, we agree with the findings of previous studies that demonstrate the significance of the 
cysteine residue at position 194 of the receptor, in the recognition of ticagrelor antiplatelet activity.    
The binding site for ticagrelor has been previously reported to be distinct from that of the orthosteric 
agonist binding site for ADP, indicating a binding modality of ticagrelor demonstrating a mode of non-
competitive action (JJ, Nilsson et al. 2009). The P2Y12R super agonist; 2MeSADP meanwhile is 
reported to act in a competitive manner with ticagrelor. We therefore investigated if this was 
affected in respect to the mutant receptor (C194A; Figure 3.7.A). Notably, unlike ADP, 2MeSADP was 
able to significantly reverse ticagrelor inverse agonist activity. Here we demonstrate significant 
differences in the level of inhibition elicited by ticagrelor alone between wild-type and mutant cells 
(**** = P < 0.0001, n = 3). Additionally, we report significant differences in delta-BRET values 
achieved with 2MeSADP alone between wild-type and mutant cells (**** = P < 0.0001, n = 3). 
Therefore, suggesting the cysteine residue located at position 194 of the receptor to be crucial in 
respect to the binding site of ticagrelor, as well as indicating overlap between the binding sites of the 





Figure 3.6. Importance of C194A mutation on ticagrelor binding site. HEK293T cells were transiently 
transfected with either wild-type P2Y12R, or mutant P2Y12R (C194A) and associated G-proteins. 
Wild-type and mutant cells were both treated with either ticagrelor (10 µM) (A), cangrelor (10 µM) 
(B) or AR-C66096 (10 µM) (C) for 10 minutes and delta-BRET measurements taken immediately 
after this elapsed incubation time. Significant differences in mean delta-BRET values were analysed 
via one-way ANOVA with Bonferroni’s multiple comparisons post-hoc test. Data plotted represent 





Figure 3.7. C194A mutation importance for agonist and antagonist activity. A) HEK293T cells were 
transiently transfected with either wild-type P2Y12R, or mutant P2Y12R (C194A) and associated G-
proteins. Wild-type and mutant cells were preincubated with ticagrelor (10 µM) for a total time of 
10 minutes. 2MeSADP was added at minute-7 and allowed to incubate for 3 further minutes. 
Following this total elapsed time of 10 minutes, delta-BRET measurements were taken accordingly. 
B) Molecular dynamics simulations were performed and crystal structure images of P2Y12R, with 
ticagrelor bound, were kindly generated by Sukhvinder Bancroft, Mundell laboratory.  Significant 
differences in mean delta-BRET values between conditions were analysed via one-way ANOVA with 
Bonferroni’s multiple comparisons post-hoc test. Data plotted represent the mean + SEM, n = 3. ns = 





3.1.7. Reversibility of ticagrelor and other P2Y12R antagonists. 
Ticagrelor has been hailed as the first orally bioactive and reversible P2Y12R antagonist, providing a 
higher degree of efficacy than the previously described antiplatelet agents (Husted and van Giezen 
2009).  However, clinically relevant adverse side effects with ticagrelor; as well as the other 
antiplatelet therapeutics, exist in the form of increased bleeding profiles. Therefore, when evaluating 
the pharmacodynamics of antiplatelet therapies, the mode of action, onset and reversibility of each 
agent becomes fundamental in the subsequent assessment of relative efficacy. This in turn influences 
their use within a clinical setting. Therefore, we designed reversibility experiments as shown in Figure 
3.8., to assess the “off-set” of ticagrelor activity.  
HEK293T cells, transiently transfected with P2Y12R and associated G-proteins, were incubated with 
antagonist (10 µM; 10 minutes). Following which, cells were then centrifuged and either resuspended 
in the existing supernatant (unwashed). Alternatively, the centrifuged cells had their supernatant 
aspirated and fresh phenol-free media introduced, followed by resuspension of the cell pellet. This 
was subsequently repeated, centrifuging the cells again and resuspending the cell pellet once more 
in phenol-free media (washed). Importantly, there were no statistical differences in the delta-BRET 
values achieved with ticagrelor incubation alone in unwashed cells compared to that of cells that 
underwent washing steps (Figure 3.8.A.) (ns = P > 0.9999, n = 3). Additionally, there were no 
significant differences in mean delta-BRET values observed in cells treated with the concomitant 
administration of ticagrelor + ADP, between unwashed and washed cells (ns = P = 0.6807, n = 3).  
Conversely, washing steps produced a statistically significant decrease in mean delta-BRET 
measurements, versus unwashed cangrelor-treated cells (* = P = 0.0479, n = 3) (Figure 3.8.B). 
Additionally, a reversal of the BRET-signal was observed in cells that underwent washing steps that 
were then subsequently treated with cangrelor + ADP (**** = P < 0.0001, n = 3). 
The reversibility of the active metabolite of prasugrel (R-138727), an established irreversible 
antagonist at the P2Y12R was next assessed (Figure 3.8.C). Unsurprisingly, washing produced no 
significant differences in the BRET-signal achieved by R-138727 alone or the effects of this antagonist 
upon ADP-stimulated P2Y12R activity, between unwashed cells and cells that underwent washing 
steps. An assessment of AR-C66096 reversibility was also performed (Figure 3.8.D). Like cangrelor, 
washing reversed AR-C66096-dependent inhibition of ADP-stimulated P2Y12R activity [green and blue 





Figure 3.8. Anti-platelet agent reversibility.  Transiently transfected HEK293T cells, with P2Y12R and 
associated G-proteins, were pre-incubated with either ticagrelor (10 µM) (A), cangrelor (10 µM) (B), 
R-138727 (10 µM) (C) or AR-C66096 (10 µM) (D) for 10 minutes, immediately followed by 
centrifugation. Cells were then either resuspended in the existing supernatant (unwashed) or 
alternatively, the supernatant aspirated and fresh untreated media introduced to resuspend the cell 
pellet. Subsequently, cells were centrifuged and resuspended in fresh media once more (washed). 
BRET measurements were taken immediately after the elapsed incubation time of the antagonist 
(10 minutes). Concurrently, cells were pre-treated with each antagonist (10 µM) for 7 minutes. At 
which time, ADP (10 µM) was added for 3 minutes, such that the total time of inhibitor incubation 
was 10 minutes. BRET measurements were taken immediately following the elapsed incubation 
time of the inhibitor. Significant differences in mean BRET values were analysed via one-way ANOVA 
with Tukey’s multiple comparisons post-hoc test. Data plotted represent the mean ± SEM, n = 3. ns 
= P > 0.05, * = P <0.05, *** = P < 0.001.  
In summary, the data above demonstrates that the active metabolite of prasugrel (R-138727), an 





activity of ticagrelor also appears irreversible. Conversely, cangrelor and AR-C66096; established 
reversible P2Y12R antagonists, appear reversible after washing steps.  
 
3.1.8. Clinical implications of antiplatelet therapy switching guidelines. 
It is not uncommon for antiplatelet therapies to be switched within the clinical setting. However, 
guidelines indicating their appropriate use; particularly in scenarios whereby emergency 
percutaneous coronary intervention is indicated, until recently were not clearly defined (Angiolillo, 
Rollini et al. 2017). Consequently, switching is broadly characterised as: 
i) escalation; switching from a less intensive to more intensive agent (clopidogrel to ticagrelor 
or prasugrel  
ii) de-escalation; from a more intensive to less intensive agent (ticagrelor or prasugrel to 
clopidogrel), or  
iii) change; switching between similarly efficacious agents (ticagrelor to prasugrel or vice 
versa).   
Therefore, we employed preincubation experiments as shown below in Figures 3.9. and 3.10., to 
assess if there were any significant differences in the level of inhibition achieved with the 
coadministration of the P2Y12R antagonists.  
HEK293T cells transiently transfected with P2Y12R and associated G-proteins were pre-incubated with 
either cangrelor or ARC-66096 (10 µM) for 30 minutes, followed by ticagrelor administration (10 µM) 
for 5 minutes. Following which, delta-BRET measurements were immediately taken (Figure 3.9.). 
There was no significant difference in the BRET-signal observed between AR-C66096 alone, and 
coadministration of AR-C66096 + ticagrelor (Figure 3.9.A) (ns = P > 0.9999, n = 3). Similarly, no 
significant differences were observed in the BRET-signal achieved between cangrelor alone, and the 
concomitant administration of cangrelor + ticagrelor (Figure 3.9.B) (ns = P > 0.9999, n = 3). 
Intriguingly, a significant difference in the BRET-signal achieved between R-138727 alone and the 
coadministration of R-138727 + ticagrelor was observed (Figure 3.9.C) (** = P = 0.0025, n = 3). 
Indicating potential synergism between ticagrelor and the thienopyridine active metabolite, 





The assessment of the clinical switching modality of de-escalation was subsequently performed, as 
shown below in Figure 3.10. The preincubation of ticagrelor (10 µM) for 30 minutes was performed 
before the subsequent addition of an additional P2Y12R antagonist (10 µM) for 5 minutes. 
Immediately following the elapsed incubation time of the additional antagonist, delta-BRET 
measurements were taken. No significant differences in the BRET-signal achieved with ticagrelor 
alone, and the coadministration of ticagrelor + cangrelor were observed (Figure 3.10.A) (ns = P = 
0.3577, n = 3). Additionally, there were no significant differences observed in the BRET-signal elicited 
by ticagrelor alone in respect to the concomitant administration of ticagrelor + R-138727 (Figure 





Figure 3.9. Pre-incubation of antagonists before ticagrelor (Escalation). Transiently transfected 
HEK293T cells were pre-incubated with AR-C66096 (10 µM) (A), cangrelor (10 µM) (B) or R-138727 
(10 µM) (C) for 30 minutes, followed by incubation with ticagrelor (10 µM) for 5 minutes. Following 
the elapsed incubation time of both inhibitors, delta-BRET measurements were taken, whereby the 
data plotted represents the mean + SEM, n = 3. Statistically significant differences between 
conditions were analysed via one-way ANOVA with Bonferroni’s multiple comparisons post-hoc test. 





Figure 3.10. Pre-incubation of ticagrelor before antagonists (De-escalation). Transiently transfected 
HEK293T cells were pre-incubated with ticagrelor (10 µM) for 30 minutes, followed by incubation 
with either cangrelor (10 µM) (A) or R-138727 (10 µM) (B) for 5 minutes. Following the elapsed 
incubation time of both inhibitors, delta-BRET measurements were taken, whereby the data plotted 
represents the mean + SEM, n = 3. Statistically significant differences between conditions were 





3.2. Ticagrelor-dependent inhibition of ADP-mediated aggregation in human platelet-
rich plasma. 
All studies above were in a cell-based system. To further characterise some of the pharmacodynamic 
qualities of ticagrelor (onset and offset) in a more physiologically and clinically relevant system, we 
used human platelets.  
Light transmission aggregometry (LTA) is a widely used diagnostic tool, utilised in the assessment of 
platelet function and additionally in the evaluation of patients with suspected bleeding disorders, ex 
vivo. The core principles of LTA have barely changed since its initial description over 50 years ago 
(O'Brien 1961). As described in 2.2.2., the technique involves the isolation of human platelet-rich 
plasma (PRP) from whole blood that is included within a cuvette, placed between a light source and 
photocell. The isolated PRP appears cloudy, due to the suspension of platelets within the plasma. 
Therefore, light is impeded within the sample. Under conditions whereby the platelets are stimulated 
with an agonist such as ADP, the platelets consequently aggregate, thus permitting light transmission 
through the sample which is detected by the photocell and measured as a function of time.    
  
3.2.1. Inhibition of agonist-induced aggregation by ticagrelor in human platelets.  
The results previously described (Figures 3.1-3.10) led to questions regarding whether we can 
replicate this within a system where the P2Y12R is not forcefully expressed (as seen in transiently 
transfected HEK293T cells). Therefore, experiments regarding the inhibitory effect of ticagrelor 
within a platelet-based system were required in respect to providing confidence in our previous 
results. Consequently, concentration-dependence LTA experiments were employed within a system 












Figure 3.11. ADP concentration-response curve in human isolated platelets. Human platelet rich 
plasma was stimulated with increasing concentrations of ADP, in the presence and absence of 
incubated ticagrelor (300 nM, 10 mins). % aggregation measurements began immediately following 
agonist addition and continued for an elapsed time of 2 mins. Data plotted represents % aggregation 
achieved upon [agonist] (M) addition, displayed as mean + SEM. EC50 value (ADP) (with 95% CI) = 
1.67 µM (1.326 - 2.052, n=3). EC50 value (ADP + ticagrelor 300 nM) = 4.47 µM. 
 
3.2.2. Assessment of the onset of action of ticagrelor in human platelets. 
Following the confirmation of the concentration-dependence of agonist activity in human PRP (Figure 
3.11.), coupled with the results of experiments regarding the initial determination of the onset of 
action of ticagrelor in transiently transfected HEK293T cells (Figure 3.3.A.), we designed and 
employed a time course assay of ticagrelor administration utilising LTA in human platelet-rich plasma, 
shown below (Figure 3.12.). The aim of this experiment was to assess the onset of action of ticagrelor 
administration in respect to time (mins), measuring the functional readout following platelet 
activation; aggregation (%). Here, we demonstrate there to be no significant differences in the % 
aggregation achieved between PRP treated with ticagrelor (300 nM), in respect to vehicle (0.1% 
DMSO) at all time points (ns = P > 0.05, n = 4). Significant differences in % aggregation was observed 
at all time points for ticagrelor (1 µM), in respect to vehicle (** = P = 0.0040, N = 4). Interestingly, we 
observe a significant decrease in the max % aggregation elicited in PRP subsequently treated with 
ticagrelor (10 µM), at all corresponding time points in respect to vehicle (0.1% DMSO) (**** = P < 





Figure 3.12. Time course assay of ticagrelor administration in human PRP.  Human platelet rich plasma 
was incubated with varying concentrations of ticagrelor; vehicle (0.1% DMSO), 300 nM, 1 µM or 10 
µM for either; 10, 60, 120 or 240 minutes. Immediately following the elapsed incubation time for 
each respective ticagrelor-treated aliquot of PRP, platelets were stimulated with ADP (10 µM) and % 
aggregation measurements were recorded. Data plotted represent the maximum % aggregation 
elicited following stimulation with ADP (10 µM) for each treatment [ticagrelor] (M) and time point 
(mins), respectively. Data is displayed as the mean + SEM, n = 4. Significant differences in % 
aggregation between conditions was assessed via one-way ANOVA with Dunnett’s multiple 
comparisons post-hoc test. Pairwise comparisons are made in respect to Vehicle control (0.1% DMSO) 
for each respective time point. Vehicle vs. ticagrelor; **** = P < 0.0001.  ** = P < 0.01. ns = P > 0.05. 
 
3.2.3. Ticagrelor reversibility in human platelet-rich plasma.  
Following the results from Figure 3.8., we sought to determine whether the reversibility of ticagrelor 
can be achieved within a platelet-based system. The reversibility of drug administration is 
fundamental when considering determinations about the offset of action of the respective 
antiplatelet agent. Therefore, we employed subsequent reversibility experiments regarding 
ticagrelor administration in human PRP (Figure 3.13.). Analysis of the data gathered below (Figure 
3.13.) indicates there were no significant differences in the % aggregation measurements achieved 
in PRP treated with ticagrelor (1 µM vs. 10 µM) before washout, after washout 1 and after washout 





Figure 3.13. Ticagrelor reversibility in human PRP. Human platelet rich plasma was isolated as 
indicated in 2.2.1. The isolated PRP was divided into 3 aliquots. The first aliquot was treated with 
either ticagrelor (10 µM or 1 µM) or vehicle (0.1% DMSO) for 10 minutes. Following the elapsed 
incubation time for aliquot 1, the treated PRP was stimulated with ADP (10 µM) and LTA 
measurements taken immediately following this, as indicated in 2.2.2. Consequently, generating % 
aggregation values corresponding to the respective treatment before subsequent washout steps as 
indicated above (Before washout). Concurrently, the second aliquot was similarly treated with 
ticagrelor (10 µM) or vehicle (0.1% DMSO) for 10 minutes. Following this, treated PRP in aliquot 2 
was centrifuged to remove the supernatant (PPP), forming a pellet of platelets. The pelleted platelets 
were then resuspended in fresh, untreated PPP and subsequently stimulated with ADP (10 µM), 
generating aggregation values for each treatment (veh, 1uM or 10uM tic) that was indicated as ‘after 
washout 1’. The same procedure of treatment, centrifugation and resuspending was applied to the 
third aliquot of PRP, such that stimulation occurred following a second successive washout (After 
washout 2). Data plotted represent the maximum % aggregation elicited following stimulation with 
ADP (10 µM) for each treatment [ticagrelor] (M) and respective washout step. Data presented as the 
mean + SEM. Significant differences in % aggregation between groups was analysed via 2-way ANOVA 
with Dunnett’s multiple comparisons post-hoc test. [veh vs. 1 µM ticagrelor = ****, p < 0.0001 (37.30-
56.14)], [veh vs. 10 µM ticagrelor = ****, p < 0.0001 (45.31-64.25)], [1 µM ticagrelor vs. 10 µM 
ticagrelor = ns, p = 0.0948 (-1.310-17.53)].   
In summary, the above data (Figures 3.11-3.13) demonstrates that the utility of P2Y12R inhibition via 
ticagrelor administration can be replicated ex-vivo, in a platelet-based system. Thus, additionally 
providing confidence that the results obtained in previous BRET experiments align with that seen in 





Chapter 4: Discussion  
  
4.1. Antiplatelet therapies for the treatment of acute coronary syndromes. 
Patients with acute coronary syndromes often require emergency intervention strategies to mitigate 
epicardial damage that results from coronary vessel occlusion. The functional responses elicited by 
platelets at sites of vessel injury is known to be a major player in the pathogenesis of the disease. 
Notably, resulting from the auto- and paracrine release of inflammatory mediators such as ADP that 
promotes the formation of pro-thrombotic platelet aggregates via P2Y12R activation and resultant 
signal transduction. As such, antiplatelet therapies utilise a combination of drugs that target multiple 
pro-thrombotic signalling pathways including the P2Y12R. Antagonism of that have cemented 
themselves as cornerstones of vascular medicine. 
Following an ACS, the aim for clinicians is to prevent any further vessel occlusion that results from 
inappropriate platelet aggregation via pro-thrombotic platelet activation. The clinician may prescribe 
one of several different P2Y12R inhibitors, in combination with aspirin (Figure 1.7), for the 
prophylactic treatment of the disease. Drawbacks in the therapeutic efficacy of the older generation 
of P2Y12R inhibitors, termed thienopyridines (ticlopidine & clopidogrel; see figure 1.8 & 1.9), became 
evident with various caveats in treatment resulting with their use. Notably, these include patients 
who are non-responsive or resistant to treatment especially to clopidogrel. In patients not responsive 
to clopidogrel therapy, prasugrel (figure 1.10) has offered some respite, addressing the 
inconsistencies in the formation of the active metabolite within patients who are identified as non-
responders/resistant. Conversely, there are some patients who are prone to bleeding upon 
antiplatelet therapy, potentially due to the irreversible blockade of P2Y12R for the lifespan of the 
platelets by the thienopyridines clopidogrel and prasugrel.     
Newer generations of P2Y12R inhibitors have been ushered into clinical practice to fill these shortfalls 
in therapeutic efficacy. The newest iteration are the cyclopentyl-triazolo-pyrimidines, ticagrelor and 
cangrelor (see figure 1.11). Ticagrelor has been shown to be clinically superior to that of the 
previously prescribed P2Y12R inhibitors, both in clinical trials and laboratory studies. Possible reasons 
for the observed clinical superiority seen with ticagrelor may be, in part, due to novel mechanisms of 





The central aim of this thesis was to further elucidate the pharmacodynamics of ticagrelor 
antiplatelet therapy that may contribute to its reported superiority in the clinical setting. As such, 
two distinct but interrelated areas were investigated:  
1) The utility of ticagrelor to act as an inverse agonist at the human P2Y12R, attenuating basal 
constitutive activity.  
2) To determine whether ticagrelor is reversible versus the endogenous P2Y12R agonist, ADP.    
 
4.2. The inverse agonist utility of ticagrelor. 
According to the classical two-state model of receptor function, receptors can exist in an equilibrium 
between an active (R*) and inactive state (R) (Figure 4.1). A ligand has two properties that determines 
its biological activity within a receptor population: affinity and intrinsic efficacy. Affinity refers to the 
ability of any ligand to bind to a given receptor and intrinsic efficacy describes the effect the drug has 
on the receptor that causes a change in receptor activity. Agonists bind with higher affinity to the 
active state of the receptor (R*) and enriches a larger proportion of the receptor population to adopt 
a signalling conformation (R*), demonstrating positive intrinsic efficacy and is a function of 
conformational selection. The ability of agonists to produce varying maximal responses via the same 
receptor allows for varying degrees of positive intrinsic efficacy and therefore an agonist can be 
described as partial, giving a submaximal response, or full, giving the maximal response.  
Figure 4.1. Simplified schematic illustration of the two-state model of receptor function. A receptor is 
said to exist between two states under equilibrium. Agonists preferentially bind to the active state 
of the receptor (R*), keeping the receptor in a signalling conformation (R*) (conformational 
selection). Antagonists bind to the active (R*) or inactive (R) state of the receptor and block the 
intracellular signalling elicited by an agonist.  
Conversely, antagonists bind with equal affinity to both R and R*, but they do not elicit a biological 








decrease the probability of an agonist to bind to a receptor by binding to an orthosteric (competitive) 
or allosteric (non-competitive) site. This traditional iteration of drug-receptor theory is predicated on 
the assumption that receptors in a given population exist in an inactive, non-signalling conformation 
unless acted upon by a ligand that has agonist activity (both affinity & intrinsic efficacy at the 
receptor). However, the two-state model was initially designed to only describe ligand-gated ion 
channels. As such, with the discovery of receptor populations that can signal in the absence of an 
agonist, termed constitutive activity, the three-state model is now the ‘simplest’ currently accepted 
multiple active state model of GPCR function (Figure 4.2A).  
Figure 4.2. The three-state model of receptor function. A) illustrative diagram of the currently 
accepted, three-state model of receptor function. B) Illustrative graph demonstrating the utility of 
inverse agonists within a receptor population that exhibits constitutive activity. (Berg and Clarke 
2018).  
The demonstration of constitutive activity was first reported in reconstituted beta-2 adrenergic 





following addition of Gαs G-protein isolated from human erythrocytes (Cerione, Codina et al. 1984). 
Soon after, studies demonstrated that endogenously expressed delta-opioid receptors (WT) (NG108-
15 cells) exhibit constitutive activity via intrinsic Gαi-coupling in the absence of a ligand (Costa and 
Herz 1989). Together, these studies help to facilitate the expansion of the previously accepted 
framework of drug-receptor theory and consequently added a new dimension to the toolbox of 
pharmacology, inverse agonism. Unlike agonists, ligands that increase receptor activity, inverse 
agonists are ligands that reduce basal receptor activity (Berg and Clarke 2018).   
The human purinoceptor P2Y12 was first demonstrated to exhibit basal constitutive activity following 
the stable expression of a P2Y1&12R chimera in cell lines (Ding, Kim et al. 2006). The constitutive 
activity displayed by P2Y12 is suggested to be a normal feature of the receptor (Garcia, Maurel-Ribes 
et al. 2018), and additionally thought to be a contributor to the occurrence of platelet hyperactivity 
seen in patients with diabetes mellitus (type II) (Hu, Chang et al. 2017). Ding et al additionally 
revealed potent inverse agonist activity of the P2Y12R antagonist, AR-C78511. More recently, work 
from the Mundell laboratory confirmed the observation of inverse agonism at the receptor, both in 
cell lines and human platelets (Aungraheeta, Conibear et al. 2016).  The inverse agonism observed 
was elicited by ticagrelor, which increased platelet cAMP and vasodilator-stimulated phosphoprotein 
phosphorylation (pVASP) in an agonist-independent manner. In addition, ticagrelor was 
demonstrated to inhibit the platelet ENT1 transporter. This thesis further characterises the mode of 
action of ticagrelor at the receptor-G-protein which may influence its perceived clinical superiority 
over the previously described antiplatelet therapies.  
Employing BRET2 assays in HEK293T cells transfected with P2Y12R and associated G-proteins, we 
sought to assess the pharmacodynamic effects of ticagrelor on receptor activation at the G-protein 
level.  As described in 3.1 (see figure 2.2), a change in the BRET ratio correlates to either receptor 
activation or inactivation. For example, a decrease in the BRET signal correlates to G-protein 
dissociation and is hence interpreted as receptor activation. Initial studies validated this assay system 
with the endogenous agonist ADP stimulating a time- and concentration-dependent increase in 
P2Y12R activity. The data from these experiments gave confidence that the BRET2 assay was viable 
following the transient transfection of P2Y12R and associated G-proteins.  
The inhibitory effect of ticagrelor alongside a range of P2Y12R antagonists (all at 10 µM) was 





increased the delta BRET signal, indicating receptor inactivation. Importantly, incubation with the 
P2Y12R antagonist AR-C66096 produced no change in the BRET signal, indicative that it is a neutral 
antagonist (see figure 4.2). This demonstrates that not all the antiplatelet drugs utilised within our 
BRET2 assay caused a change in the BRET signal.  Additionally, this result is further evidence that 
ticagrelor does not appear to behave as a traditional antagonist but rather as an inverse agonist. 
Furthermore, the lack of change in the BRET signal in response to treatment of ticagrelor to mu-
opioid receptor transfected cells (figure 3.5D) serves as a negative control experiment, and evidence 
that the inhibition resulting from ticagrelor is specific to the P2Y12R. Interestingly, cangrelor 
incubation resulted in a similar reversal of the ADP-mediated response to that seen with ticagrelor. 
However, the max BRET signal achieved by cangrelor incubation alone was roughly half of that 
observed with ticagrelor. This would suggest that cangrelor also has inverse agonist activity at the 
P2Y12R. This aligns with similar findings from previous studies utilising BRET technology in P2Y12R-
transfected HEK293 cells (Garcia, Maurel-Ribes et al. 2018). 
Further detailed study of both the concentration- and time-dependence of ticagrelor and cangrelor 
was performed. Both produced a sustained reduction in receptor activity for the duration of the assay 
(60 mins) although that of cangrelor was lower than ticagrelor. The concentration-dependence of 
ticagrelor-alone and cangrelor-alone administration revealed EC50s of 208 nM (70 – 587 nM, n = 4) 
and 62 nM (33 – 117 nM, n = 5), respectively. This assessment of relative potency is comparable with 
that reported from previous studies (Cattaneo 2010). Our data suggests cangrelor to be more potent 
than ticagrelor but with a markedly reduced Emax. Therefore, in respect to ticagrelor, cangrelor 
potentially behaves as a partial inverse agonist whereas ticagrelor behaves as a full inverse agonist. 
The distinction between full and partial agonism is understood to refer to the relative intrinsic 
efficacy that can be achieved by different drugs at the same receptor. A possible reason for the noted 
difference in intrinsic efficacy found between cangrelor and ticagrelor has been suggested to be as a  
result of biased inverse agonism attributed to cangrelor (Garcia, Maurel-Ribes et al. 2018). Functional 
selectivity gives rise to the phenomenon of biased agonism and refers to the ligand-dependent 
preferential activation of selective intracellular signalling pathways at the same receptor (Urban, 
Clarke et al. 2007). Importantly, ticagrelor’s superiority in P2Y12R inhibition has been attributed and 
suggested to be due to the inactive conformation of the receptor adopted with ticagrelor treatment 





4.3. Ticagrelor antagonism of ADP-stimulated platelet aggregation.  
Further evidence of ticagrelor activity at the P2Y12R in a physiologically relevant context was 
exemplified in platelets via LTA (see figures 3.11 & 3.12).  As outlined previously in 3.2, LTA is a widely 
utilised diagnostic tool that facilitates the assessment of the inhibitory effect of antiplatelet 
therapeutics on the pro-thrombotic response of platelet aggregation. In agreement with previous 
studies (Jarvis, Humphries et al. 2000) and as shown in figure 3.11, ADP increased platelet 
aggregation in a concentration-dependent manner. Preincubation of platelets with ticagrelor (300 
nM) caused a visible rightward shift of the dose-response curve for ADP-stimulated platelet 
aggregation. This is indicative of effective P2Y12R inhibition by ticagrelor. Furthermore, this selected 
concentration of 300 nM ticagrelor is comparable with that found under physiological conditions in 
patients, with reported plasma concentration ranging from 0.4 – 1.5 µM (Storey, Husted et al. 2007). 
Subsequent time course experiments of ticagrelor action in human PRP were performed (figure 3.12) 
to assess the speed of onset and duration of ticagrelor antiplatelet therapy. Ticagrelor at 1 µM & 10 
µM effectively inhibited ADP-induced (10 µM) platelet aggregation across a range of time points in a 
concentration-dependent manner. The onset of ticagrelor action was rapid, complementing our 
results observed in previous BRET2 experiments (see figure 3.3). Interestingly, ticagrelor action did 
not display any reversal in platelet inhibition at the 240-minute time point at all concentrations, 
indicating the stability of ticagrelor in this assay platform and potentially the reversibility of 
ticagrelor, which is discussed in detail later.    
 
4.4. Ticagrelor-dependent inhibition of the ENT1 transporter.      
Previous work from the Mundell laboratory has suggested there to be a second novel mechanism of 
action of ticagrelor aside from the inverse agonist activity at the P2Y12R, as a result of inhibition of 
platelet-expressed ENT1 (Aungraheeta, Conibear et al. 2016). Inhibition of ENT1 was shown to lead 
to an accumulation of extracellular adenosine, capable of activating Gαs-coupled A2A receptors. 
Mundell and colleagues suggest this may in part contribute to the adenosine-related side effects 
reported with ticagrelor use, dyspnoea.  We sought to assess if this additional novel mode of action 
contributed to the effect, if any, on the mode of action of ticagrelor at the P2Y12R in our BRET2 cell-
based system (figure 3.5A-D). These studies revealed that the preincubation of either apyrase, XAC 
or forskolin had no effect on the BRET signal achieved by ticagrelor when compared to ticagrelor-





no change in the BRET signal when treated with ticagrelor-alone. As outlined in 3.1.5, the data from 
these experiments serve as further controls and give confidence that the inverse agonist utility seen 
at the P2Y12R is indeed specific to the mode of action of ticagrelor.    
The therapeutic usefulness of inverse agonists rests on the assumption that the enhanced 
constitutive activity present within a given receptor population contributes to the disease pathology. 
It has now been identified that platelets from patients with diabetes mellitus type II express 
constitutively activated P2Y12Rs (Hu, Chang et al. 2017), increasing the risk of prothrombotic 
complications in this subset of patients. Therefore, ticagrelor’s superiority within the clinical setting 
may be explained in part by its inverse agonist activity. To further define the pharmacodynamics of 
ticagrelor antiplatelet therapy, we sought to assess the reversibility of the drug both in cell lines and 
in human platelets. 
    
4.5. Importance of C194 on the P2Y12R for ticagrelor activity   
The binding site of ticagrelor at the P2Y12R has been under debate for some time (VAN Giezen, Nilsson 
et al. 2009, von Kügelgen, Lutz et al. 2014, Parker and Storey 2016). It has now been established that 
the active metabolites for the thienopyridines, clopidogrel and prasugrel, exert their antagonist 
effect via their interaction with the cysteine residue at position 97 of the P2Y12R (Hoffmann, Lutz et 
al. 2014). Hoffmann and colleagues utilised further mutagenesis experiments and identified C194 as 
a cysteine residue within the P2Y12R, to be crucial for the recognition of ticagrelor’s antagonist 
activity.  
As shown in figure 3.6, C194A mutation in the P2Y12R resulted in a significant reduction of both 
ticagrelor’s inverse agonist activity and ability to antagonise ADP. ADP-stimulated P2Y12R activity was 
unaffected by the C194A mutation. This difference between ADP and ticagrelor activity is further 
evidence supporting the non-competitive mode of action of ticagrelor. This is comparable to the 
findings from Mundell and colleagues (Aungraheeta, Conibear et al. 2016), previous mutagenesis 
studies(Garcia, Maurel-Ribes et al. 2018) and studies from others (VAN Giezen, Nilsson et al. 2009). 
Notably, the C194A mutation had no effect on the antagonist activity of the inverse agonist, 
cangrelor, as well as the neutral antagonist AR-C66096. The data shown in figure 3.6 therefore gives 
confidence that the cysteine residue at position 194, within TM5 of the receptor protein is crucial in 





Further study using the synthetic agonist 2MeSADP further confirmed that C194 residue is important 
for the recognition of ticagrelor (*** = P < 0.001, n = 3). Ticagrelor was previously shown to act as a 
competitive antagonist at the P2Y12R versus 2MeSADP. Notably, we show that 2MeSADP agonist 
activity is significantly reduced by the C194A mutation. This indicates that this cysteine residue is also 
important for 2MeSADP agonist activity and that the binding site for ticagrelor and 2MeSADP 
potentially overlap.  This data was additionally exemplified via molecular dynamic simulations (see 
figure 3.7B) and further evidence that ADP binds to the P2Y12R independently from ticagrelor and 
indicating C194 seems important for 2MeSADP activity.  Overall, this data help to define the unique 
binding modality of ticagrelor that may influence both its reversibility at the P2Y12R, and its perceived 
superiority over the previously described antiplatelet agents.  
 
4.6. Is ticagrelor reversible? 
The reversibility of a drug correlates to the ratio of the rate constant of dissociation of the ligand 
from the receptor (Koff) and the rate constant of association of the ligand to the receptor (Kon). This 
ratio of Koff/Kon is known as the dissociation constant (Kd), the inverse of the ligand’s affinity for the 
receptor protein (Tonge 2018). This, in turn, is influenced by the intramolecular forces between the 
functional groups of the ligand, interacting with that of the substituent amino acid residues within 
the receptor’s binding pocket. This pharmacodynamic parameter of drug reversibility is crucially 
important to consider when assessing the safety and efficacy of pharmacological therapeutics in the 
context of drug discovery and pharmacovigilance (Strelow 2017).  
The reported clinical superiority in efficacy of ticagrelor over other previously described antiplatelet 
agents is clear, as outlined above (see 1.15.5). However, the untenable side effect profile of 
spontaneous major bleeding and bleeding during invasive procedures exists and remains with 
ticagrelor, as with all antiplatelet agents. In respect to the thienopyridines, clopidogrel and prasugrel, 
the cause for this unwanted bleeding is thought in part to be due to their mode of action and 
irreversible blockade of the P2Y12R. These drugs effectively attenuate platelet function for the 
duration of their lifespan.  
The need for reversible P2Y12R antagonists especially in the context of antiplatelet drug switching in 
patients undergoing emergency invasive procedures such as PCI and CABG is clear. Ticagrelor has 





2014). However, clinical and laboratory evidence has emerged contesting ticagrelor’s reversibility at 
the P2Y12R. The results from the PLATO study demonstrated ticagrelor to be more advantageous than 
clopidogrel in platelet inhibition, however both displayed similar bleeding profiles during invasive 
procedures (James, Akerblom et al. 2009). In this study, ticagrelor was withheld for 24-72 hours and 
clopidogrel for 5 days. The reported half-life of ticagrelor is approximately 7 hours, so it is perhaps 
surprising the degree of bleeding found in patients. More recently, in-vitro studies have emerged 
suggesting platelet supplementation via transfusion may not rescue platelet inhibition resulting from 
ticagrelor action (Martin, Berndt et al. 2016). Furthermore, ticagrelor-targeted monoclonal antibody 
fragments have been engineered, appearing efficacious in the rapid reversal of the drug (Bhatt, 
Pollack et al. 2019) (Zhang, Xu et al. 2019).  The data from these studies ultimately underscores the 
inconsistencies in the reported reversibility of ticagrelor.  
Initially, we used our cell-based BRET assay to assess ticagrelor reversibility. Notably, the inverse 
agonist activity of ticagrelor was not reduced following multiple washing steps. In addition, ticagrelor 
antagonist of ADP-stimulated P2Y12R activity persisted following washing. Notably, both cangrelor’s 
inverse agonist activity and antagonism of ADP-stimulated P2Y12R was reversed following washing 
steps (figure 3.8B). As expected, ADP-stimulated activity could not be restored following washing in 
cells treated with R-138727, an irreversible antagonist, whilst AR-C66096 antagonism could be 
reversed by washing. The data with both cangrelor and AR-C66096 shows that cell washing could 
effectively remove ligand.  
Ultimately, ticagrelor shows minimal reversibility and is more akin to R-138727. Moreover, when 
compared with that of the reversible inverse agonist cangrelor, ticagrelor appears to bind to the 
P2Y12R irreversibly.  
To complement our cell line studies we performed similar experiments in human platelets (figure 
3.13). As in our cell line studies, ticagrelor-dependent inhibition of ADP-stimulated platelet 
aggregation failed to reverse following platelet washing. This is further evidence of the suggested 
irreversibility of ticagrelor at the P2Y12R and ultimately gives confidence in the accuracy of the results 
obtained from previous BRET2 reversibility experiments (figure 3.8). It appears that ticagrelor, in our 





4.7.  Implications of switching guidelines on P2Y12R stabilisation.  
As outlined in 3.1.8, a clinical concern regarding the use of all antiplatelet agents is the risk of DDIs 
when switching pharmacotherapies. Switching is common, especially in patients who are to undergo 
emergency invasive procedures. Consequently, expert consensus guidance for switching antiplatelet 
therapies has emerged (Angiolillo, Rollini et al. 2017). Angiolillo and others characterise switching as 
escalation, de-escalation or change. Escalation refers to the switching from a less-intensive to a more-
intensive antiplatelet agent. De-escalation refers to the switching from a more-intensive to a less-
intensive agent. Change refers to the switching between similarly efficacious agents. The 
pharmacodynamics of antiplatelet agents, and particularly their reversibility profile is therefore a 
crucial parameter to consider in the context of influencing antiplatelet agent use in clinical practice. 
This thesis describes data regarding the effect of concomitant antiplatelet agent treatment on the 
level of inhibition achieved at the G-protein/receptor level of the P2Y12R.     
We firstly sought to determine if ticagrelor was able to act on the P2Y12R if the receptor was 
preincubated with a range of P2Y12R antagonists. Cell line studies revealed that preincubation with 
either the neutral antagonist AR-C66096 or partial inverse agonist cangrelor blocked ticagrelor action 
at the P2Y12R. This may indicate that a large proportion of the receptor population once occupied by 
either of these ligands blocks subsequent ticagrelor binding to the receptor. Notably, R-138727 
preincubation followed by ticagrelor treatment resulted in a significant increase in the level of P2Y12R 
G-protein association that surpassed that achieved by both R-138727-alone and ticagrelor-alone 
treated cells (** = P < 0.01, n = 3). This result suggests that the concomitant administration of a 
thienopyridine alongside ticagrelor may result in a greater degree of inverse agonist activity, and 
hence greater inhibition of P2Y12R agonist-mediated signal transduction. This data confirms 
suggestions from previous clinical studies indicating the potential for DDIs when switching from 
prasugrel to ticagrelor (Rollini, Franchi et al. 2016). This result may indicate that R-138727 perhaps 
changes the conformation of the P2Y12R and its ligand binding pocket such that subsequent ticagrelor 
binding may enable the receptor to adopt a more inactive conformation.  
We secondly sought to establish whether ticagrelor effects could be reversed by adding other P2Y12R 
antagonists. None of the ligands (AR-C66096, R-138727 or cangrelor) were able to reduce ticagrelor 
activity. Ultimately the data from the experiments in figure 3.10 suggest that the switching modality 
of de-escalation, switching from a more intensive agent to a less intensive one, may not induce any 





observed potentiation in G-protein association resulting from preincubation of R-138727, followed 
by treatment with ticagrelor (escalation). The explanation of this phenomenon is unclear, however 
certainly warrants further extensive investigation in platelets and in a clinical setting. Ongoing 
molecular modelling should hopefully provide at least a greater mechanistic understanding of this 
phenomenon.   
 
4.8. Experimental limitations & future direction. 
This thesis describes data characterising the molecular mechanisms of ticagrelor action at the human 
P2Y12R, both in cell lines and in human platelets. As such, experimental limitations exist in this study 
and must be considered.  
1) The BRET2 technology employed in experiments in this thesis  may contain intrinsic limitations 
that could influence observed results. The BRET2 technique requires the successful transient 
transfection of the P2Y12R and associated G-proteins. Following the successful recombination 
of the P2Y12R at the cell membrane, BRET2 technology facilitates a highly sensitive assessment 
of intracellular G-protein dissociation (P2Y12R activation) and association (P2Y12R 
stabilisation) via the mechanism previously outlined in 3.1 (see figure 2.2). It must be noted 
that the fused constituents (RlucII & GFP10) to the G protein-subunits may cause steric 
hindrance, and perhaps may not accurately reflect observations seen in wild type 
interactions. To assess the level of receptor activation more accurately in the context of 
ticagrelor action, stable cell lines expressing the receptor could perhaps be utilised and 
GTPase assays employed.  
 
2) Receptor/G-protein over-expression in cell lines may induce constitutive activity. Increased 
G-protein could lead to more coupling in the absence of agonist and therefore this may 
produce false negatives. Additionally, increased receptor expression achieved by transient 
transfection may further enhance the signal detected by the BRET system. The results in this 
thesis therefore may not accurately represent what takes place with the P2Y12R in platelets. 
In this study, DNA expression via transfection was controlled at constant levels (1 µg), 
however we did not quantify P2Y12R surface expression. To address this, Immunofluorescence 





be performed, providing a quantifiable comparison of P2Y12R expression levels between our 
HEK293T cell line and platelets. In addition, further studies characterising how changes in 
receptor expression could impact upon basal receptor activity should be performed. Ideally, 
these studies would be undertaken with both the P2Y12R and another Gi-coupled GPCR (i.e. 
µ-opioid receptor). This would allow us to determine if simply overexpression of any receptor 
increases basal receptor reactivity, or if it is a fundamental property of the P2Y12R.  
 
3) The BRET2 data in this thesis came from studies performed solely in HEK293T cells. In the 
future, additional cell lines could be utilised to account for any cell-line specific caveats.   
 
4) When designing and employing the LTA experiments exemplified in figures 3.11-3.13, a 
limitation to consider was the potential incidence of interindividual variability in platelet 
responses observed between healthy blood donors. Additionally, the process of platelet 
isolation requires centrifugation and increased sample manipulation. Therefore, the 
incidence of unwanted platelet activation may have influenced these results. To address 
these caveats, experiments in platelets assessing changes in intracellular cAMP following 
treatment with ticagrelor should be undertaken.   
 
5) In this study, all experiments were carried out on independent days and at least in triplicate 
(n=3), following standard lab procedure.  Many scientific peer-reviewed journals now require 
a minimum of n=5 for successful submission. It must be noted that some key experiments in 
this study did not meet the n=5 criteria that is now required. However, the data collected by 
each independent experiment was an average of quadruplicate measurements for each 
treatment. Additionally, among replicates between experiments, the data was very 
consistent. Therefore, although some key experiments not meeting the current criteria for 
submission to a peer reviewed journal, we ultimately have confidence in the reproducibility 
of our results.  
 
 It is important to consider the future direction of the work within this thesis, especially in the context 





elucidates the pharmacodynamics of ticagrelor antiplatelet therapy at the human P2Y12R, a more 
comprehensive understanding of the molecular interactions underpinning its perceived clinical 
superiority are still needed. For example, a more detailed exploration of competitive/non-
competitive interactions of ticagrelor with that of the P2Y12R could be employed. How ticagrelor 
activity is affected by a range of P2Y12R ligands could be explored using detailed pharmacological 
analysis (i.e. Schild plot analysis). This data would be even more powerful if it were backed by In-
Silico docking techniques and molecular modelling/dynamics. The combination of these approaches 
may provide a more mechanistic insight into the interactions of ticagrelor with that of the receptor.  
Further molecular dynamics could be used to assess specific amino acid residues that may confer 
both ticagrelor activity and irreversibility. Site directed mutagenesis of potential P2Y12R/ticagrelor 
interacting residues could further help define ticagrelor’s mode of action.  
  
4.9. Final conclusions. 
The data in this thesis has further defined the parameters that contribute to the pharmacodynamics 
of ticagrelor antiplatelet therapy at the human P2Y12R. It appears increasingly likely that the reported 
superiority of ticagrelor in clinical settings may be the result of both the inverse agonist activity of 
ticagrelor and the suggested irreversible molecular interaction of ticagrelor with the receptor. This 
irreversibility may also contribute in part to the increased bleeding risk seen in patients and the 
tangible clinical concerns evidenced by the recent development of ticagrelor reversal agents (Bhatt, 
Pollack et al. 2019). Moreover, the data presented may help to further inform the newly described 
guidelines for antiplatelet switching, of which the accurate characterisation of the 
pharmacodynamics of each drug is imperative. In the context of ticagrelor, the interesting 
pharmacology exhibited at the P2Y12R is a demonstration of the therapeutic usefulness of inverse 
agonism, allowing clinicians greater control of receptor function and thus expected to translate to a 
better treatment of vascular disease.  
Considering the wide-spread use of DAPT in the treatment of ACS and the increased efficacy of 
ticagrelor over the previously described antiplatelet agents, coupled with that from projected 
increases in the incidence of the disease globally, it appears that ticagrelor may be prescribed more 
in the future, potentially as a monotherapy. Therefore, the accurate characterisation of the 
pharmacodynamics of ticagrelor; its mode of action, onset and reversibility is even more critical. For 





mechanism of action was fully elucidated (Maffrand 2012). Ticagrelor was first approved for use in 
the EU, December 3rd, 2010 and July 20th, 2011 by the US FDA. Therefore, it is entirely possible that 
the characterisation of ticagrelor action at the P2Y12R will continue to evolve.  
Most recently, a novel coronavirus outbreak (COVID-19) has circulated the world, resulting in a global 
pandemic. The disease state caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has been reported to affect multiple organ systems. Notably, patients with diabetes mellitus, 
obesity and/or hypertension are at markedly increased risk of mortality (Dariya and Nagaraju 2020). 
Further evidence has emerged suggesting cardiac troponin I levels are elevated in patients with 
severe infection (Imazio, Klingel et al. 2020), indicative of cardiac injury. Additionally, platelet-rich 
microthrombi are reported to be present in the vasculature of the lungs, heart, kidneys and liver of 
patients infected with the virus (Rapkiewicz, Mai et al. 2020). Moreover, megakaryocytes were 
identified to be localised in the microvasculature of the heart, glomeruli and the lungs as well as 
increased numbers in the bone marrow. This may indicate a heightened prothrombotic response of 
platelets in COVID-19.  
Therefore, antiplatelet therapies may become increasingly indicated in the future and thus may 
result in the increased clinical use of ticagrelor. The results from this thesis further defines the 
pharmacodynamics of ticagrelor antiplatelet therapy and gives insight into its molecular 
pharmacology contributing to its perceived clinical superiority, which may in turn help to inform the 
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